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Abstract 
In industrialized countries, campylobacteriosis is the most common cause of human 
gastroenteric infection. It is mainly caused by Campylobacter jejuni and Campylobacter 
coli, but the pathogenic role of other species, such as Campylobacter hyointestinalis, 
remains unclear due to difficulties in cultivating these fastidious bacteria. Humans most 
often become infected by ingesting contaminated water or food, especially undercooked 
chicken. Campylobacteriosis is normally a self-limiting disease, but in severe cases the 
patients are treated with antimicrobial agents. The predominant antimicrobial agents for 
treating Campylobacter infections are erythromycin and ciprofloxacin. However, during 
the past few decades resistant C. jejuni and C. coli strains have emerged at an alarming 
rate due, at least partly, to the large-scale use of these agents in food production animals. 
Understanding of the mechanisms underlying bacterial resistance can reveal the risks 
involved in using antimicrobials in animal husbandry and ultimately help in preventing 
antimicrobial resistance, which has life-threatening implications in human and animal 
health. It was therefore the aim of this thesis to study the various resistance mechanisms of 
C. jejuni, C. coli and C. hyointestinalis towards antimicrobial agents. 
Finnish C. hyointestinalis strains are susceptible to most antimicrobials of veterinary 
importance. When susceptibility to 12 different antimicrobials was tested, all the reindeer 
strains proved susceptible, but in bovine strains resistance was observed in 32% and 24% 
of the strains to streptomycin and sulphonamides, respectively. Since unlike bovines, 
reindeer are very rarely treated with antimicrobials, the difference in the susceptibility 
profile of the bovine and reindeer strains most probably reflects the veterinary use of these 
substances in bovine husbandry, but not in reindeer. 
Quinolone resistance in C. jejuni and C. coli has been associated with mutations in the 
quinolone resistance-determining region (QRDR) of gyrA. Unlike these two species, C. 
hyointestinalis is intrinsically resistant to nalidixic acid. To explain this phenomenon, 
studies were conducted with the QRDR of C. hyointestinalis. The QRDR showed 73% 
identity with that of C. jejuni, but mutations associated with nalidixic acid resistance in C. 
jejuni were not found in C. hyointestinalis. However, inherent nalidixic acid resistance in 
C. hyointestinalis was associated with efflux pumps since the efflux pump inhibitor, 
PAβN, decreased the nalidixic acid resistance in C. hyointestinalis 2- to 8-fold. However, 
susceptibility was not obtained, indicating the presence of other resistance mechanisms. 
By inducing ciprofloxacin resistance in C. hyointestinalis, also the nalidixic acid MIC 
values increased, indicating significant cross-resistance between these two agents. High-
level ciprofloxacin resistance (> 32 mg/l) in C. hyointestinalis was associated with the 
same Thr86-Ile mutation in QRDR as in C. jejuni, but QRDR mutations did not explain 
resistance at lower ciprofloxacin levels. 
An efflux pump system, CmeABC, has been established to play an important role in 
the resistance of C. jejuni and C. coli to various antimicrobial agents. When the effect of 
efflux pump effectors on antimicrobial susceptibility of C. jejuni and C. coli was 
evaluated, the efflux pump inhibitor PAβN emerged as the most potent. It increased the 
susceptibility of C. jejuni and C. coli to erythromycin and rifampicin 8- to 32-fold and 8- 
to 64-fold, respectively. Another inhibitor, NMP, decreased erythromycin, rifampicin and 
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tetracycline MIC values of C. jejuni and C. coli 1- to 8-fold, 2- to 8-fold and 1- to 4-fold, 
respectively. The different results produced by these two inhibitors indicate a different 
mode of function for these pump inhibitors. Of the two tested efflux pump inducers, 
sodium salicylate produced a modest effect in the MIC values for ciprofloxacin and 
rifampicin, and bile salt had no observable effect on the MIC values of the studied 
antimicrobials, nor did it have any observable impact on the mutation frequencies of C. 
jejuni and C. coli strains.  
Since ciprofloxacin and erythromycin resistance in C. jejuni and C. coli involve a 
mutation in a target gene, the mutation frequencies of C. jejuni and C. coli strains were 
determined. The mutation frequency values differed strongly between different strains, 
from hypomutable to strongly hypermutable. The relatively large proportion (25%) of 
hypermutable strains may facilitate the adaptation of C. jejuni and C. coli to selective 
environments. No correlation was seen between the mutation frequency values and 
mutations in the QRDR or the promoter binding region of cmeABC after ciprofloxacin 
exposure. 
The emergence of QRDR mutations was evaluated by subjecting originally 
ciprofloxacin-susceptible C. jejuni strains to low-level (0.125 or 1 mg/l) ciprofloxacin 
concentration and determining the changes in ciprofloxacin MIC values and alterations in 
the QRDR sequence data. After DNA extraction and sequencing of the QRDR of the 
ciprofloxacin-exposed strains, multiple peaks were observed at nucleotide positions 256 
and 267 in the QRDR-sequencing chromatograms, possibly reflecting different QRDR 
subpopulations. However, some variants produced ciprofloxacin MIC levels of up to 
16 mg/l, even though no peaks corresponding to mutated nucleotides in the QRDR were 
observed; this suggests the presence of a QRDR-independent resistance mechanism. In 
subsequent persistence studies, different QRDR subpopulations were able to persist and 
co-exist in both the presence and absence of low-level ciprofloxacin concentration; 
however, the QRDR-independent resistance mechanism was quickly replaced by QRDR 
mutations in the persistence of ciprofloxacin challenge.  
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1 Introduction 
Campylobacter species are small, spirally curved and highly motile bacteria that are 
commonly found in most animal species. Twenty-one Campylobacter species have 
currently been validly characterized, the most important pathogenic species being 
Campylobacter jejuni and to a lesser extent Campylobacter coli (Euzéby, 1997; 
http://www.bacterio.cict.fr/, accessed December 2009). In humans, they cause illness, 
campylobacteriosis, which is the most common cause of human gastroenteric infection in 
industrialized countries and is responsible for diarrhoea in an estimated 400–500 million 
people globally each year (Allos, 2001; Ruiz-Palacios, 2007). The role of other 
Campylobacter species, such as Campylobacter hyointestinalis, in human and animal 
disease may be greatly underestimated due to difficulties in cultivating these fastidious 
and sensitive bacteria. While their impact on disease burden has earlier been thought to be 
negligible, improved identification methods are likely to increase the detected numbers of 
these rarer Campylobacter species (Logan et al., 2001).   
Some of the Campylobacter species (see Table 1) are zoonotic pathogens, and humans 
most often become infected by ingesting contaminated food or water. The most common 
sources are raw or uncooked meat, especially poultry, contact with animals, unpasteurized 
milk and contaminated drinking water (Harris et al., 1986; Adak et al., 1995; Olson et al., 
2008). Cases are usually sporadic, although outbreaks do occur as a result of, for example, 
contamination of drinking water. Infection has been experimentally induced with as few as 
500 organisms (Robinson, 1981). After an incubation period of 1–5 days, symptoms, 
including diarrhoea, abdominal pain and fever, appear. Campylobacteriosis is normally a 
self-limiting disease, and the symptoms usually resolve in a week. In some cases, late-
onset complications may occur, namely reactive arthritis (in 1- to 5% of Campylobacter-
infected patients) (Pope et al., 2007) and Guillain-Barré syndrome (in 0.01–0.03% of 
Campylobacter enteritis patients) (McCarthy and Giesecke, 2001; Tam et al., 2006). 
In severe cases, patients are treated with antimicrobial agents (Allos, 2001). The most 
common antimicrobial agents for treating Campylobacter infections are macrolides, such 
as erythromycin, and fluoroquinolones, such as ciprofloxacin (Blaser and Engberg, 2008). 
However, resistant Campylobacter strains have recently emerged at an elevated rate due, 
at least partly, to the large-scale use of these agents in food production animals (Blaser and 
Engberg, 2008). 
Although a number of different classes of antimicrobials exist, bacteria possess and are 
able to acquire many different mechanisms that allow them to evade the action of these 
substances. The rate at which the pharmaceutical industry has been introducing new 
antibiotics has been inadequate to guarantee successful therapy against all pathogenic 
bacterial strains. Understanding of the mechanisms underlying bacterial resistance could 
lead to the development of new agents to challenge bacterial resistance mechanisms.  
The aim of this thesis was to study the various resistance mechanisms of C. jejuni, C. 
coli and C. hyointestinalis towards antimicrobial agents. Special attention was given to 
ciprofloxacin, whose role as a key antimicrobial in the treatment of campylobacteriosis 
has lately been compromised due to the rapid and forceful emergence of ciprofloxacin-
resistant strains.  
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Specifically, the susceptibility profile of Finnish C. hyointestinalis strains was established 
and the effect of antimicrobial use in the host animals was discussed. Differences in 
quinolone resistance between C. hyointestinalis and C. jejuni were also investigated. The 
predisposition of C. jejuni and C. coli to develop resistance was investigated by 
establishing mutation frequencies of these species. The effect of low-level ciprofloxacin 
exposure and the development of resistance in C. jejuni and C. coli were evaluated by 
observing alterations, variation and development of mutations in the gene fragment coding 
for the ciprofloxacin target site subsequent to ciprofloxacin challenge. Finally, the action 
of efflux pump effectors on the susceptibility of C. jejuni, C. coli and C. hyointestinalis 
towards several antimicrobials was elucidated to assess the efflux mechanism in these 
species and to evaluate the potential of the putative efflux pump inhibitors in therapy. 
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2 Review of the literature 
2.1 Campylobacter spp. 
Bacteria with Campylobacter-like morphology were first isolated from domestic animals 
about a century ago (McFadyean and Stockman, 1913), but it was not until the 1970s that 
these bacteria began to become more widely recognized as human pathogens (Dekeyser et 
al., 1972, Skirrow, 1977). Today, Campylobacter are recognized as the most important 
cause of bacterial gastrointestinal infection in humans. In 2008, there were 4453 
laboratory-confirmed cases of Campylobacter infection in Finland (National Infectious 
Disease Registry, National Institute for Health and Welfare, Finland, 
http://www3.ktl.fi/stat/). Approximately 70–80% of these infections were acquired abroad 
(EFSA, 2009a). 
Campylobacter species belong to the epsilon class of proteobacteria. Twenty-one 
validly named Campylobacter species currently exist (Euzéby, 1997; 
http://www.bacterio.cict.fr/, accessed December 2009). Members of the family 
Campylobacteraceae are Gram-negative, curved or spiral rods, that are 0.2–0.8 µm wide 
and 0.5–5 µm long (Debruyne et al., 2008). They require a microaerobic growth 
environment and are typically motile with a single unsheathed flagellum at one or both 
ends of the cell (Debruyne et al., 2008). Campylobacter spp. have been isolated from a 
large variety of different animals, and each Campylobacter species seems to favour certain 
animal species. 
Campylobacter jejuni has been isolated from many different domestic and wild 
animals, where it is considered a harmless commensal of the gastrointestinal tract, 
although occasionally it has been associated with animal diseases (Euzéby, 1997; 
http://www.bacterio.cict.fr/, accessed December 2009). The avian gut is a particularly 
preferred reservoir for C. jejuni because it possesses optimal growth conditions such as a 
temperature of 42°C. In humans, C. jejuni is responsible for the great majority of enteric 
Campylobacter infections (80–90%) (Fitzgerald et al., 2008). Since broiler chickens are 
often colonized with C. jejuni (see Table 6), eating or handling undercooked chicken meat 
is considered one of the most important risk factors for human campylobacteriosis (Olson 
et al., 2008). 
Campylobacter coli is responsible for an estimated 5–10% of Campylobacter 
infections (Fitzgerald et al., 2008). C. coli and C. jejuni are closely related and often 
difficult to differentiate (Debruyne et al. 2008). Like C. jejuni, C. coli can be isolated from 
many animal species, foods and environmental samples. The primary reservoir for C. coli 
is pigs, up to 100% of which can be C. coli-positive (Saenz et al., 2000).  
Some other Campylobacter species have also been associated with human disease 
(Table 1), but in most studies the growth conditions are optimized for the selection of C. 
jejuni and C. coli, leaving other Campylobacter species, including Campylobacter 
hyointestinalis, often undetected and their actual prevalence underestimated. 
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Table 1. Campylobacter species associated with human disease (Euzéby, 1997; 
http://www.bacterio.cict.fr/, accessed December 2009) 
 
* Pathogenic role unclear  
 
C. hyointestinalis has been commonly isolated from many animals, notably cattle; 32% of 
faecal samples tested positive for C. hyointestinalis in a study by Atabay and Corry 
(1998), and 17.2% tested positive in a study by Inglis et al. (2005). In Finland, 15.3% of 
bovine faecal samples and 6% of reindeer faecal samples have tested positive for this 
species (Hänninen et al., 2002; Hakkinen and Hänninen, 2009). C. hyointestinalis has also 
been associated with enteritis in pigs (Gebhart et al., 1985a), deer (Hill et al., 1987), cattle 
(Diker and Ozlem, 1990) and humans (Fennell et al., 1986; Edmonds et al., 1987; Minet 
et al., 1988; Salama et al., 1992; Gorkiewicz et al., 2002). The species C. hyointestinalis 
Campylobacter 
species 
Source Human disease Animal disease
C. coli Pigs and other 
domestic animals 
Gastroenteritis, 
septicaemia, abortion 
Gastroenteritis, 
abortion 
C. concisus* Humans Periodontal disease, 
gastroenteritis 
Not known 
C. curvus* Humans Periodontal disease, 
gastroenteritis, reflux 
disease 
Not known 
C. fetus  Cattle, sheep Septicaemia, systemic 
infection, abortion,  
Abortion 
C. gracilis* Humans Periodontal disease, deep 
tissue infection, 
abscesses, pneumonia, 
empyema, ischial wound 
Not known 
C. hyointestinalis  Cattle, pigs, deer, 
humans  
Gastroenteritis 
 
Enteritis 
C. jejuni  Humans, poultry and 
other animals 
Gastroenteritis, 
septicaemia, meningitis, 
abortion, proctitis, 
Guillain-Barré syndrome 
Gastroenteritis, 
hepatitis, 
abortion 
C. lari* Poultry and other 
animals 
Gastroenteritis, 
septicaemia 
Gastroenteritis 
C. rectus* Humans Periodontal disease, 
abscesses, reflux disease, 
appendicitis 
Not known 
C. showae* Humans  Periodontal disease Not known 
C. sputorum* Domestic mammals, 
humans 
Abscesses, gastroenteritis Not known 
C. upsaliensis Dogs, cats, humans Gastroenteritis, abortion, 
septicaemia, abscesses 
Gastroenteritis 
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includes two subspecies, namely hyointestinalis and lawsonii. The latter has been isolated 
from pigs, but its clinical significance is yet unknown, whereas C. hyointestinalis subsp. 
hyointestinalis has been associated with animal and human diarrhoea. At the genome 
level, C. hyointestinalis is a very diverse species (On and Vandamme, 1997) and is closely 
related to Campylobacter fetus, which is a major cause of septic abortion in domestic 
animals and is also implicated in human illnesses (Lastovica and Allos, 2008). In this 
thesis, C. hyointestinalis refers to C. hyointestinalis subsp. hyointestinalis. 
2.2 Antimicrobial agents 
Antimicrobial agents are defined as substances able to inhibit or kill micro-organisms. 
They can be synthetic or semi-synthetic compounds or antibiotics: substances produced by 
other micro-organisms. The major antibacterial classes are listed in Table 2 according to 
their mode of function and chemical structure. 
 
Table 2. Major antibacterial classes (Prescott, 2004) 
 
Antibacterial class Exemplary drugs Target 
Cell wall inhibitors   
Beta-lactams Penicillins: penicillins, 
ampicillin, amoxicillin  
Cephalosporins: cefalexin 
Carbapenems: meropenem 
Monobactams: aztreonam 
Transpeptidase 
Protein synthesis inhibitors 
Aminoglycosides Gentamicin, streptomycin, 
kanamycin 
30S ribosomal subunit 
Lincosamides Lincomycin, clindamycin 50S ribosomal subunit 
Tetracyclines Tetracycline, doxycycline 30S ribosomal subunit 
Macrolides Erythromycin, tylosin 50S ribosomal subunit 
Phenicols Chloramphenicol 50S ribosomal subunit 
Nucleic acid inhibitors   
Sulfonamides Trimethoprim, bactrim Pteroate synthetase 
Nitroimidazoles Metronidazole Nucleotides/DNaseI 
Quinolones Ciprofloxacin,  nalidixic acid Type II topoisomerases 
RNA synthesis inhibitors   
Rifamycins Rifampicin RNA polymerase 
 
 
The discovery of penicillin in 1928 by Alexander Fleming was the beginning of modern 
antibiotic medicine. Mass production started in the 1940s, and today hundreds of 
antimicrobials are available on the market. An estimated half of the globally produced 
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antimicrobials are used for food animals (World Health Organization, 2002). 
Antimicrobials are used in animals as therapeutics, prophylactics and growth promoters. 
According to a European survey, in 1997, approximately 100 mg of antimicrobials were 
used for every kilogram of meat destined for human consumption, and almost all 
antimicrobials used in animals were identical or related to substances used in human 
medicine (Committee for Veterinary Medicinal Products, 1999). Table 3 presents recent 
information about the amount of meat produced and antimicrobials used in animals in four 
European countries.  
 
Table 3. Meat production and animal consumption of antimicrobials in four different 
European countries in 2007 or 2008 
 
Country 
Slaughtered animals for meat 
production in 2008 (Eurostat, 2009) 
(tonnes) 
Amount of 
antimicrobials used in 
animals (tonnes) 
Finland 401 300 17.0a 
Sweden 526 200 16.4b 
Denmark 2 013 600 120.2c 
France 5 623 700 1179d 
a In 2008 (Finnish Medicines Agency, 2009b) 
b In 2008 (National Veterinary Institute (SVA), 2009) 
c In 2008 (DANMAP 2008, 2009), only food animals 
d In 2007 (Chevance and Moulin, 2009) 
 
In 2006, the European Union banned the use of all antibiotics as growth promoters in its 
member states. In Finland, the use of antimicrobials in animals has been monitored since 
1995, at which time the total consumption was about 18 000 kg. Consumption declined to 
its lowest point (about 13 000 kg) in 2003, but has since increased to 16 997 kg in 2008 
(Table 3; Finnish Medicines Agency, 2009b). In Finland, β-lactams are the most 
commonly used antimicrobials in animals (58%), followed by tetracyclines (18%) and 
sulphonamides (17%) (Finnish Medicines Agency, 2009b). 
A total of 21.68 defined daily dose/1000 inhabitants/day (DDD/1000 inh/day) of 
systemic antibacterials were used in 2008 in human medicine according to Finnish sales 
statistics (Finnish Medicines Agency, 2009a). Beta-lactam antibacterials were used most, 
9.83 DDD/1000 inh/day, followed by tetracyclines, 4.24 DDD/1000 inh/day (Table 4). 
Campylobacteriosis is usually a self-limiting disease, but in certain cases the use of 
antimicrobials is justified, e.g. when the disease affects elderly people or people with 
underlying illnesses or when the symptoms are prolonged or unusually severe (Allos, 
2001). The drug of choice for treating campylobacteriosis is erythromycin, followed by 
ciprofloxacin, and alternative therapeutic agents include tetracycline and aminoglycosides 
(Blaser and Engberg, 2008; Murray et al., 2009). 
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Table 4. List of fluoroquinolones, macrolides and tetracyclines on the Finnish market and use of these substances in human and veterinary 
medicine in 2008 (Finnish Medicines Agency, 2009a; Finnish Medicines Agency, 2009b) 
 
Fluoroquinolones Macrolides Tetracyclines 
Human medicine Veterinary medicine Human medicine Veterinary medicine Human medicine Veterinary medicine 
Ciprofloxacin 
Levofloxacin 
Moxifloxacin 
Norfloxacin  
Ofloxacin 
Danofloxacin 
Difloxacin 
Enrofloxacin 
Ibafloxacin 
Azitromycin 
Claritromycin 
Erythromycin 
Roxitromycin 
Telitromycin 
Spiramycin 
Tulatromycin 
Tylosin 
Doxicycline 
Lymecycline 
Tetracycline 
Tigecycline 
Oxytetracycline 
Chlortetracycline 
1.25 
DDD/1000 inh/daya 
90 kgb 1.45 
DDD/1000 inh/day
847 kg 4.24  
DDD/1000 inh/day 
3022 kg 
a defined daily dose/1000 inhabitants/day 
b amount of active ingredient
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2.2.1 Ciprofloxacin 
 
Ciprofloxacin (Figure 1) is structurally a fluoroquinolone antimicrobial. It is a broad-
spectrum, synthetic antimicrobial agent commonly used to treat many bacterial infections, 
including campylobacteriosis. Nalidixic acid, a predecessor to fluoroquinolone 
antimicrobials, belongs to the quinolone class of antimicrobials. Sitafloxacin is a new-
generation fluoroquinolone that is more effective than ciprofloxacin against C. jejuni 
strains, including those with a gyrA mutation (Sato et al., 1992; Lehtopolku et al., 2005), 
but its approval in Europe is unlikely because in Caucasians sitafloxacin has been 
associated with mild ultraviolet phototoxicity reactions (Dawe et al., 2003). In Finland, 
less than 1% of antimicrobials used in animals are fluoroquinolones (Finnish Medicines 
Agency, 2009b). The most commonly used fluoroquinolone in animals is enrofloxacin, the 
main metabolite of which is ciprofloxacin (Küng et al., 1993). Fluoroquinolones used in 
human and veterinary medicine in Finland are presented in Table 4. 
 
 
 
 
Figure 1. Molecular structure of ciprofloxacin 
 
Ciprofloxacin acts by inhibiting DNA synthesis. In a living bacterial cell, DNA is in a 
negatively supercoiled form. These negative supercoils are removed by a topoisomerase II 
DNA gyrase, and the daughter chromosomes are separated by topoisomerase IV, allowing 
replication and transcription to take place (Drlica and Zhao, 1997). Quinolones act by 
binding these topoisomerases, and in Gram-negative bacteria the quinolones interact 
primarily with gyrase and DNA, thus inhibiting supercoiling and possibly forming a 
cytotoxic complex leading to cell death (Maxwell, 1992). 
 
2.2.2 Erythromycin 
Erythromycin is a macrolide antibiotic, produced from a strain of Saccharopolyspora 
erythraea. Its molecular structure is provided in Figure 2. Macrolides used in human and 
veterinary medicine are presented in Table 4. Macrolides and lincosamides represented 
about 5% of antimicrobials used in animals in Finland in 2008 (Finnish Medicines 
Agency, 2009b). 
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Figure 2. Molecular structure of erythromycin 
 
The mode of action of erythromycin is inhibition of protein synthesis by binding to the 
23S rRNA in the 50S ribosomal subunit (Schlunzen et al., 2001). This sterically hinders 
the binding of the peptidyl transfer RNA, which results in inhibition of translocation, thus 
halting the elongation of the developing peptide chain (Brisson-Noel et al., 1988). 
Erythromycin is the drug of choice for treating campylobacteriosis. It is a broad-spectrum, 
fairly inexpensive and well-tolerated antibiotic that is effective against Campylobacter 
spp. when administered during the first days of illness (Salazar-Lindo et al., 1986). 
2.2.3 Tetracycline 
Tetracycline (Figure 3) is a broad-spectrum antibiotic produced by bacteria in the genus 
Streptomyces. Tetracyclines used in human and veterinary medicine in Finland are 
presented in Table 4. Tetracyclines represent about 18% of the antimicrobials used in 
animals (Finnish Medicines Agency, 2009b), but in many countries, such as France, it is 
the most commonly used antimicrobial class in animals (Chevance and Moulin, 2009).  
 
 
 
 
Figure 3. Molecular structure of tetracycline 
 
Tetracycline binds to Mg2+ cations in order to pass through outer membrane porins of 
Gram-negative bacteria. In the periplasmic space, tetracycline dissociates from 
magnesium and moves passively into the cytoplasm (Chopra and Roberts, 2001). 
Tetracycline acts by binding to discrete sites on the ribosomal 30S subunit (Chopra et al., 
1992). Its primary antimicrobial effect takes place by direct steric hindrance by binding to 
the A site in the 30S subunit, thus hindering the movement of transfer RNA (Harms et al., 
2003). 
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2.3 Multiple drug resistance in Campylobacter 
According to definition, a bacterial strain can be considered resistant to a certain 
antimicrobial agent if it is able to propagate in higher concentrations in that agent than 
other strains of the same species or genus (Guardabassi and Courvalin, 2006). The 
resistance level of a particular strain can be established by determining the lowest drug 
concentration that completely inhibits the growth of the strain (minimal inhibitory 
concentration, MIC). 
Multiple drug resistance (MDR) in bacteria is associated with efflux systems and 
structural components of the cell membrane. These mechanisms control the transport of 
structurally unrelated substances in and out of the cell.  
2.3.1 Efflux systems and efflux pump effectors 
Energy-dependent drug efflux pumps are used in bacteria for extruding metabolites and 
toxic compounds, including antimicrobial agents (Li and Nikaido, 2004). In C. jejuni, 
several putative efflux systems have been identified (Parkhill et al., 2000; Ge et al., 2005). 
Of these, two systems have been characterized as conferring MDR resistance, namely 
CmeABC and CmeDEF (Lin et al., 2002; Pumbwe and Piddock, 2002; Pumbwe et al., 
2005).  
Homologous CmeABC system has also been characterized in C. coli (Corcoran et al., 
2005; Ge et al., 2005), and identified in C. lari, C. upsaliensis and C. fetus (Guo et al., 
2010). CmeABC is coded by an operon consisting of three genes, cmeA, cmeB and cmeC, 
which code for a periplasmic fusion protein, an inner membrane drug transporter and an 
outer membrane protein, respectively (Figure 4) (Lin et al., 2002). CmeB belongs to the 
resistance nodulation cell division (RND) family of efflux transporters (Pumbwe and 
Piddock, 2002). Inactivation of the CmeABC efflux pump by insertional inactivation of 
cmeB or with efflux pump inhibitors leads to increased susceptibility to a variety of 
antibiotics, bile acids and other toxic substances, including those to which Campylobacter 
are intrinsically resistant, showing that CmeABC plays a key role in both intrinsic and 
acquired resistance of Campylobacter (Lin et al., 2002; Pumbwe and Piddock, 2002; 
Pumbwe et al., 2004; Pumbwe et al., 2005; Akiba et al., 2006). CmeABC is regulated by 
CmeR, which represses the transcription of cmeABC by binding to an inverted repeat 
sequence in the 97 bp intergenic (IT) region between cmeR and cmeA (Figure 4) (Lin et 
al., 2005a). Upregulation of CmeABC has been associated with inactivation of the cmeR, 
substitutions in the substrate binding region of CmeR, a deletion or a mutation in the 
inverted repeat sequence of the promoter binding region of the cmeABC and competitive 
binding of bile salts to the promoter region of the cmeABC (Pumbwe et al., 2004; Lin et 
al., 2005a; Lin et al., 2005b; Cagliero et al., 2007).  
Another RND system, CmeDEF, has been identified in C. jejuni. It has a narrower 
substrate profile and transports, for instance, bile acids and ampicillin, but not 
ciprofloxacin, erythromycin or tetracycline (Pumbwe et al., 2005; Akiba et al., 2006). In a 
study comparing CmeABC and CmeDEF systems, cmeF was expressed at a much lower 
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level than CmeABC, but evidence exists of an interaction between these two efflux 
systems that promotes viability and resistance of C. jejuni in a hostile environment (Akiba 
et al., 2006). 
 
 
 
 
 
 
 
 
Figure 4. Genomic organization of the cmeABC operon in C. jejuni strain 81-176. A 
part of the sequence of the intergenic (IT) region between cmeR and cmeA is shown. 
The start codon (ATG) of cmeA is underlined and the inverted repeat is in bold. 
 
 
Since efflux pump systems have a key role in the antimicrobial resistance of C. jejuni and 
C. coli (Lin et al., 2002; Corcoran et al., 2005), inhibition of efflux would provide an 
important means for preventing emerging resistance and multidrug resistance in bacteria. 
To achieve this inhibition, synthetic and natural compound libraries have been screened 
with the aim of finding substances capable of reversing the action of the efflux pumps. 
After screening for efflux pump inhibitors and subsequently optimizing the properties of a 
potential compound, Renau et al. (1999) were able to produce a substance called phenyl-
arginine-β-naphthylamide (PAβN), a broad-spectrum efflux pump inhibitor. It was first 
characterized in Pseudomonas aeruginosa (Lomovskaya et al., 2001) and later studied in 
several bacteria, including C. jejuni and C. coli (Payot et al., 2004; Cagliero et al., 2005; 
Gibreel et al., 2007).  
Similarly, by screening of an N-heterocyclic organic compound library for multidrug 
reversal activity, Bohnert and Kern (2005) were able to characterize another putative 
efflux pump inhibitor, 1-(1-naphthylmethyl)-piperazine (NMP), in Escherichia coli. It has 
been shown to partially reverse multidrug resistance in some members of the 
Enterobacteriaceae and in Acinetobacter baumannii (Bohnert and Kern, 2005; Pannek et 
al., 2006; Schumacher et al., 2006). 
Salicylate is a non-steroidal anti-inflammatory pharmaceutical agent and the active 
component of aspirin, a prostaglandin synthesis inhibitor drug, commonly taken to relieve 
fever and discomfort associated with infections as well as to prevent vascular diseases 
(Weissmann, 1991). It is therefore of concern that salicylate has been associated with 
increased resistance to multiple antibiotics in several bacteria, such as E. coli and 
Salmonella serovar Typhimurium (Price et al., 2000). In E. coli, salicylic acid binds to a 
repressor protein, MarR, which leads to over-expression of the global regulatory gene 
marA. Subsequent to this, the outer membrane protein OmpF is down-regulated and the 
synthesis of the RND multidrug efflux pump AcrAB-TolC increases, which eventually 
results in decreased antimicrobial accumulation (Price et al., 2000).  
cmeA cmeB cmeC cmeR 
TATAATTAGCCAAAAATTTCTGTAATAAATATTACAATTTTTAATTTAATTTTTCAAGGCAAAACCATG 
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Bile salts are antimicrobial compounds naturally present in the animal intestine. Multidrug 
efflux pumps, such as CmeABC, contribute to the intrinsic resistance of C. jejuni to bile 
salts (Lin et al., 2003). Lin et al. (2005b) have shown that bile salts increase the 
expression of cmeABC in C. jejuni by preventing the binding of the transcriptional 
repressor CmeR, and therefore, bile salts could be considered efflux pump inducers.  
2.3.2 Role of the membrane proteins in Campylobacter resistance 
Drugs can cross the bacterial membrane and enter the cell by using porin channels or by 
diffusing through the lipid bilayer. Porin channels are postulated to be mainly used by 
relatively small drugs, such as β-lactams, tetracycline, chloramphenicol and 
fluoroquinolones, whereas large molecules, such as macrolides, diffuse slowly across the 
lipid bilayer (Nikaido, 2003). In Campylobacter, two outer membrane porins have been 
characterized: in C. jejuni and C. coli, the major outer membrane porin (MOMP) protein, 
encoded by porA, and in C. jejuni Omp50 (Pagès et al., 1989; Bolla et al., 2000). Very 
limited functional information is available about these porins, and thus far, no evidence 
has emerged that they play any role in MDR of Campylobacter (Pumbwe et al., 2004). 
2.4 Specific resistance mechanisms in Campylobacter 
2.4.1 Resistance to fluoroquinolones 
Two known resistance mechanisms that confer resistance in C. jejuni and C. coli to 
fluoroquinolones are point mutations in the quinolone-resistance determining region 
(QRDR) of gyrA and the function of the multidrug efflux pump CmeABC. 
The target for ciprofloxacin activity in C. jejuni is gyrase, which comprises two 
subunits encoded by gyrA and gyrB (Higgins et al., 1978). A single mutation in gyrA is 
able to confer resistance to ciprofloxacin by reducing the affinity of gyrases to quinolones. 
The most commonly found mutation in ciprofloxacin-resistant C. jejuni strains is the 
Thr86-Ile mutation, which results from transition of cytosine to thymine at nucleotide 256, 
conferring high-level resistance to ciprofloxacin (Charvalos et al., 1996; Mazzariol et al., 
2000; Zirnstein et al., 2000; Hakanen et al., 2002b; Piddock et al., 2003). Other reported 
mutations include Thr86-Lys, Thr86-Ala, Ala70-Thr, Pro104-Ser, Asp90-Asn, Asp90-Tyr 
and transitions at codon 119 (Charvalos et al., 1996; Ruiz et al., 1998; Zirnstein et al., 
1999; Bachoual et al., 2001; Hakanen et al., 2002b; Yan et al., 2006). These mutations are 
less frequently observed and are associated with intermediate-level fluoroquinolone 
resistance.  
In some instances, QRDR mutations have not been detected in ciprofloxacin-resistant C. 
jejuni (Hakanen et al., 2003; Piddock et al., 2003; Pumbwe et al., 2004), suggesting 
another mechanism for ciprofloxacin resistance. Studies with mutant strains where the 
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CmeABC efflux pump was inactivated by a cmeB insert showed a 4- to 8-fold increase in 
ciprofloxacin susceptibility, and accumulation studies clearly indicated an increased 
accumulation of ciprofloxacin compared with the wild-type parent strain (Lin et al., 2002; 
Pumbwe and Piddock, 2002). Experiments where MIC values well below the level of 
clinical significance were often obtained by insertional inactivation of cmeB in originally 
resistant C. jejuni strains possessing various gyrA, suggest the existence of synergism 
between these two resistance mechanisms, namely efflux and target mutations (Luo et al., 
2003).  
2.4.2 Resistance to macrolides 
Macrolide resistance in C. jejuni and C. coli involves two mechanisms, namely target 
modification and efflux. 
Mutations in 23S rRNA block the interaction of macrolide drugs with the 50S 
ribosomal subunit, and thus, confer macrolide resistance. Specifically, mutations at base 
positions 2074 and 2075 are associated with high-level macrolide resistance in C. jejuni 
and C. coli (Jensen and Aarestrup, 2001; Vacher et al., 2003; Gibreel et al., 2005; Mamelli 
et al., 2005). Mutations at these positions are likely to block the binding of macrolides to 
their inhibitory site on the 23S ribosomal subunit (Pfister et al., 2004). The predominant 
mutation in erythromycin-resistant strains is A2075G (Gibreel and Taylor, 2006), and in 
some strains these two mutations have been found to co-exist (Vacher et al., 2003; Vacher 
et al., 2005). 
The chromosome of C. jejuni and C. coli contains three copies of the 23S rRNA gene 
(Fouts et al., 2005). In erythromycin-resistant strains, generally all copies carry macrolide 
resistance-associated mutations, but the co-existence of wild-type alleles does not seem to 
affect the resistance level (Jensen and Aarestrup, 2001; Gibreel et al., 2005).  
In addition to 23S RNA mutations, mutations in ribosomal proteins L4 (G74D) and 
L22 (insertions at position 86 or 98) have been implicated in conferring macrolide 
resistance to C. jejuni and C. coli (Cagliero et al., 2006b). 
The involvement of an efflux system in the macrolide resistance of C. jejuni and C. 
coli has been demonstrated in studies using the efflux pump inhibitor β-naphtylamide 
(PAβN) (Lomovskaya et al., 2001; Payot et al., 2004; Cagliero et al., 2005; Martinez and 
Lin, 2006; Gibreel et al., 2007) and using insertional inactivation of the cmeB gene (Payot 
et al., 2004; Cagliero et al., 2005; Gibreel et al., 2007). In C. coli isolates with low-level 
erythromycin resistance (MICs 8–16 mg/l), no mutations have been detected in the target 
gene (Payot et al., 2004), and in these isolates the inactivation of CmeABC leads to 
restored susceptibility to erythromycin, suggesting the involvement of CmeABC in the 
intrinsic resistance of Campylobacter (Cagliero et al., 2005; Lin et al., 2007). In isolates 
with a high erythromycin resistance level (MIC > 128 mg/l), the resistance is associated 
with a mutation in the 23S rRNA gene (Payot et al., 2004). In these isolates, the 
inactivation of CmeABC leads to 2- to 4-fold decrease in erythromycin resistance, 
implying synergistic action with the target mutations in achieving acquired macrolide 
resistance (Cagliero et al., 2005; Cagliero et al., 2006a; Lin et al., 2007).  
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In a study by Lin et al. (2005a), a deletion in the promoter region of the cmeABC operon 
was spontaneously obtained by selection on a ciprofloxacin-containing medium. This 
resulted in increased resistance to several antimicrobials, including erythromycin, 
suggesting a possible role of promoter region mutants in the development of 
erythromycin-resistant C. jejuni strains. 
2.4.3 Resistance to tetracyclines 
Tetracycline resistance in C. jejuni and C. coli involves ribosomal protection and efflux 
mechanisms.  
The ribosomal protection is mediated by a protection protein termed Tet(O) 
(Manavathu et al., 1988) that is structurally related to translational ribosome-binding 
proteins  (Connell et al., 2003). Tet(O) is coded by a gene located on plasmids of different 
sizes and in some strains chromosomally (Lee et al., 1994; Gibreel et al., 2004). Several 
studies have demonstrated that tet(O)-carrying plasmids can be transferred via conjugation 
between C. jejuni and C. coli strains in vivo and in vitro (Avrain et al., 2004; Batchelor et 
al., 2004; Gibreel et al., 2004; Pratt and Korolik, 2005). Tet(O) acts by removing 
tetracycline bound to the A-site in the ribosomal 30S subunit (Connell et al., 2002). 
Specifically, Tet(O) induces a conformational change, which is functionally opposite to 
that of tetracycline and which allosterically distorts the tetracycline-binding site, resulting 
in the release of tetracycline (Connell et al., 2003). Even after the Tet(O) has left the 
ribosome, the induced conformation persists, thus preventing rebinding of the tetracycline 
(Connell et al., 2003).  
The multidrug efflux pump CmeABC has been implicated in intrinsic and acquired 
tetracycline resistance (Lin et al., 2002; Pumbwe and Piddock, 2002; Gibreel et al., 2007). 
Insertional inactivation of the CmeABC pump in a tetracycline-susceptible strain led to an 
8-fold increase in susceptibility, and in tetracycline-resistant isolates to a 16- to 128-fold 
decrease in tetracycline resistance (Lin et al., 2002; Pumbwe and Piddock, 2002; Gibreel 
et al., 2007). Addition of the pump inhibitor PAβN reduced tetracycline resistance less 
than 2-fold (Gibreel et al., 2007). 
2.4.4 Resistance to other antimicrobial agents 
Aminoglycosides act by binding to the decoding region in the A-site of the ribosomal 30S 
subunit. This interaction results in aberrant proteins by interfering with accurate codon-
anticodon recognition and in disruption of elongation of nascent proteins by inhibiting the 
translocation of tRNA from the A-site to the P-site (Jana and Deb, 2006). Aminoglycoside 
resistance is mediated by enzymatic modification that diminishes affinity of 
aminoglycosides for the rRNA A-site (Llano-Sotelo et al., 2002). These enzymes fall into 
three classes: aminoglycoside acetyltransferases (AAC), aminoglycoside 
adenyltransferases (AAD) and aminoglycoside phosphotransferases (APH), each of which 
has its own characteristic modification sites and substrates (Engberg et al., 2006). APH is 
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the most common enzyme found in C. jejuni and C. coli (Taylor et al., 1988; Tenover et 
al., 1992). 
β-lactam molecules enter Campylobacter through outer membrane porin channels. 
Once inside, β-lactams bind to enzymes involved in cell wall synthesis, preventing cross-
linking of the peptidoglycan network of the cell wall and resulting in the swelling and 
eventually bursting of the bacterial cell (Siu, 2002). While Campylobacter spp. are 
generally inherently resistant to many β-lactams, they remain susceptible to, for example, 
amoxicillin and ampicillin (Tajada et al., 1996). According to the study of Pagès et al. 
(1989), the pores of porins in C. jejuni and C. coli are cation-selective and so small that 
most of the large, anionic β-lactams are unable to diffuse through them. A vast majority of 
C. jejuni and C. coli isolates are also able to produce β-lactamases, which inactivate the β-
lactam molecule by hydrolysing the structural lactam ring (Sykes and Matthew, 1976; 
Tajada et al., 1996). A third mechanism for β-lactam resistance in C. jejuni is the action of 
efflux pumps. Several recent studies have demonstrated a significant increase in 
susceptibility to ampicillin in CmeABC-inactivated C. jejuni mutants and a decrease in 
susceptibility in CmeABC-overexpressing mutants (Lin et al., 2002; Pumbwe and 
Piddock, 2002; Pumbwe et al., 2005), but this phenomenon was less pronounced in 
ampicillin-resistant and β-lactamase-positive strains (Lin et al., 2002). 
Chloramphenicol inhibits bacterial protein biosynthesis by preventing peptide chain 
elongation. It binds reversibly to the peptidyltransferase centre at the 50S ribosomal 
subunit (Schlunzen et al., 2001). Chloramphenicol resistance is conferred by a plasmid-
carried cat gene that encodes acetyltransferase, which modifies chloramphenicol in a way 
that prevents it from binding to ribosomes (Schwarz et al., 2004). Although 
chloramphenicol resistance in Campylobacter is rare, a plasmid-carried chloramphenicol 
resistance gene has been reported in C. coli (Wang and Taylor, 1990). 
2.5 Antimicrobial resistance in Campylobacter spp. 
2.5.1 Intrinsic resistance 
C. jejuni, C. coli and C. hyointestinalis are considered intrinsically resistant to at least 
polymyxin B, bacitracin, novobiocin, vancomycin, certain cephalosporins and penicillins, 
rifampicin, trimethoprim and cycloheximide (Gebhart et al., 1985b; Ng et al., 1985). 
Some of these agents are often included in Campylobacter selective media to inhibit the 
growth of other bacteria, but it must be noted that not all Campylobacter species have the 
same intrinsic resistance profile. For example, C. hyointestinalis is intrinsically 
cephalothin-resistant and nalidixic acid-resistant, whereas C. jejuni and C. coli are 
nalidixic acid-susceptible and cephalothin-resistant, and Campylobacter upsaliensis is 
susceptible to both of these agents and Campylobacter lari is resistant to both of these 
agents (Lastovica and Allos, 2008).  
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Intrinsic resistance arises from insensitivity of a bacterial species, due to a structural or 
functional characteristic, to a particular antimicrobial agent. This insensitivity in 
Campylobacter may be due to the following: 
 
(1) low affinity of the antimicrobial agent for the bacterial target (e.g. trimethoprim, 
certain β-lactams) 
(2) inability of the antimicrobial agent to cross the outer membrane (e.g. certain β-lactams)  
(3) extrusion of the antimicrobial by the bacterial efflux system (e.g. rifampicin, 
polymyxin B, certain cephalosporins, novobiocin)  
(4) bacterial production of enzymes capable of inactivating the antimicrobial (e.g. β-
lactamases) (Tajada et al., 1996; Gibreel and Skold, 1998). 
2.5.2 Incidence of resistance 
Geographical differences in resistance profiles of C. jejuni are significant; however, 
resistance to antimicrobial agents of clinical importance has clearly increased over the last 
few decades. For example, in a Canadian study of human C. jejuni samples, the frequency 
of tetracycline resistance in 1980 was 6.5% and in 1999–2002 it had reached 50% (Gibreel 
et al., 2004). Similarly, in an American study fluoroquinolone resistance in human C. 
jejuni samples was found to increase from 0%  in 1995 to  40.5% in 2001 (Nachamkin et 
al., 2002) and in a Dutch study from 0% in 1982 to 32% in 2002 (van Hees et al., 2007). 
In all of the above-cited studies, erythromycin resistance, on the other hand, had remained 
at a low level (0–5%), although some studies report up to 18% and 60% resistance to 
erythromycin in human and chicken C. jejuni and C. coli isolates, respectively (Li et al., 
1998). 
Several studies have shown greater prevalence for erythromycin resistance in C. coli 
than in C. jejuni (Gibreel and Taylor, 2006). This may be explained by the pig being a 
natural host for C. coli and the chicken for C. jejuni, and macrolides being used more 
often on pig farms than on poultry farms. In addition, pigs become more exposed to 
macrolides due to their longer production cycles (Lin et al., 2007). 
An overview of the studies on resistance prevalence (%) in human C. jejuni and C. coli 
samples is presented in Table 5, and in chicken and pig C. jejuni and C. coli isolates in 
Table 6. 
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Table 5. Resistance profiles of four antimicrobial agents for C. jejuni and C. coli isolated from human faecal samples in six different 
countries, reported as percentage of resistant strains 
 
Country Isolates tested Erythromycin Ciprofloxacin Tetracycline Gentamicin C. jejuni C. coli C. jejuni C. coli C. jejuni C. coli C. jejuni C. coli 
Finland1 478 0.2 4.3 0.87  
Denmark2 185 1.6  28.1  17.3  0  
Taiwan3 93 10 50 52 75 95 85 1 15 
Canada4 203 0  2  49.8    
Germany5 430 0 29.4 46.2 41.2 38.5 35.3 0 0 
France6 5685 1.4 12.5 25.3 42.0 28.8 53.4 0 0 
1 (Schönberg-Norio et al., 2006), domestic strains only, reported as joint values for C. jejuni and C. coli strains 
2 (DANMAP 2008, 2009), domestic strains only 
3 (Li et al., 1998) 
4 (Gibreel et al., 2004) 
5 (Luber et al., 2003) 
6 (Gallay et al., 2007) 
7 Doxycycline 
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Table 6. Percentage of resistant C. jejuni and C. coli isolates isolated from chickens and pigs, respectively, and percentage of Campylobacter-
positive broiler flocks in four different European countries  
 
Country 
Campylobacter- 
positive animals1 
(%) 
Resistance to antimicrobials (%) 
Ciprofloxacin Erythromycin Tetracycline Streptomycin Gentamicin 
C. jejuni C. coli C. jejuni C. coli C. jejuni C. coli C. jejuni C. coli C. jejuni C. coli 
Finland2  7.1 1.2 8 0 0 0 0 4.9 NA 1.2 0 
Sweden3  12.6 0 30 0 1 0 2 0 57 0 0 
Denmark4  26.8 12.2 7.1 0 15.3 9.8 5.1 4.9 51.0 0 0 
France5  80.2 30.4 55.3 0 13.2 50 78.9 3.6 15.8 0 0 
1 In 2007 (European Food Safety Authority, 2009) 
2 In 2007 and 2008 (FINRES-Vet 2008, 2009; FINRES-Vet 2007, 2008), 81 C. jejuni and 62 C. coli isolates tested 
3 In 2008 (National Veterinary Institute (SVA), 2009), C. coli values are hippurate-negative thermophilic Campylobacter spp. from pigs: 38 
C. jejuni and 97 C. coli isolates tested 
4 In 2008 (DANMAP 2008, 2009), 82 C. jejuni and 98 C. coli isolates tested 
5 In 2007 (EFSA, 2009b), C. coli values from chicken: 56 C. jejuni and 76 C. coli isolates tested 
 
 
 
 
28
2.5.3 Fitness and pathogenicity of resistant Campylobacter 
 
Campylobacter resistance to a particular antimicrobial is often a result of a mutation in the 
gene encoding the target site of that antimicrobial. These target sites, such as DNA gyrase 
and RNA polymerase, are essential for bacterial propagation, and mutations encoding 
these sites may result in reduced fitness of these bacteria in the absence of selective 
pressure by antimicrobials (Andersson and Levin, 1999). Contrary to this, 
fluoroquinolone-resistant C. jejuni strains showed enhanced fitness and the ability to out-
compete fluoroquinolone-susceptible strains when these two strains were inoculated into 
chickens (Luo et al., 2005). This finding is supported by epidemiological studies revealing 
the prevalence of fluoroquinolone-resistant C. jejuni and C. coli on chicken farms for at 
least 1–4 years after the farms had stopped using fluoroquinolones (Pedersen and 
Wedderkopp, 2003; Price et al., 2005). Interestingly, this fitness is not explained by 
compensatory mutations, but is directly linked to the Thr86-Ile mutation in gyrA (Luo et 
al., 2005). Likewise, tetracycline-resistant C. jejuni strains have shown evidence of 
enhanced fitness. Tetracycline resistance in C. jejuni is conferred by the tet(O)-plasmid 
obtained by horizontal transfer even in the absence of antimicrobial selection pressure 
(Avrain et al., 2004). In studies by Luangtongkum et al. (2008), tetracycline-resistant 
Campylobacter strains were able to co-exist or replace tetracycline-susceptible strains on 
organic poultry farms. 
In contrast to fluoroquinolone- or tetracycline-resistant Campylobacter, erythromycin-
resistant Campylobacter are less fit in the absence of the selection pressure, and hence, are 
rapidly outcompeted by susceptible wild-type strains (Luangtongkum et al., 2009). Similar 
conclusions can be drawn from such countries as Denmark, where by reducing the amount 
of macrolides used in food animals the numbers of macrolide-resistant C. coli rapidly 
decreased (Aarestrup et al., 2008).    
Enhanced fitness of resistant Campylobacter strains causing campylobacteriosis may 
have implications for human health. Enhanced fitness of resistant strains is likely to 
increase the number of resistant strains also in human clinical samples. In addition, in 
some studies fluoroquinolone-resistant Campylobacter strains have been demonstrated to 
prolong disease, lengthening the duration of diarrhoea by an average of 3 days, compared 
with disease inflicted by fluoroquinolone-susceptible strains (Smith et al., 1999; Engberg 
et al., 2004; Nelson et al., 2004). Both quinolone- and macrolide-resistant strains have 
been associated with increased risk of invasive illness or death, compared with susceptible 
strains. This risk was calculated to be 6-fold greater for quinolone-resistant strains and >5-
fold greater for macrolide-resistant strains (Helms et al., 2005). However, the opposite 
results have also been obtained, with ciprofloxacin-susceptible isolates being associated 
with more severe disease (Feodoroff et al., 2009). In a re-analysis of ciprofloxacin-
resistant C. jejuni infections, Wassenaar et al. (2007) concluded that fluoroquinolone-
resistant Campylobacter infections are no more severe than infections with susceptible 
bacteria. 
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2.5.4 Development of resistance 
Mutations play a major role in Campylobacter resistance. Several mechanisms have been 
reported to contribute to the emergence of these mutations: 
Whole-genome analyses have revealed that C. jejuni lack many of the genes encoding 
DNA repair molecules present in other bacteria, e.g. mutH and mutL (methyl-directed 
mismatch repair), sbcB (recombination repair), phr (repair of pyrimidine dimers) and vsr 
(very short patch repair), as well as genes protecting from UV-induced mutagenesis 
(umuCD) and alkylating agents (ada gene) (Parkhill et al., 2000; Fouts et al., 2005; Zhang 
et al., 2006), facilitating the appearance of mutations. 
Emergence of mutations conferring fluoroquinolone resistance in C. jejuni has been 
associated with Mfd, a transcription-repair coupling factor, as Han et al. (2008) recently 
showed that Mfd increases the frequency of mutations associated with fluoroquinolone 
resistance and that ciprofloxacin upregulates the mfd gene encoding this molecule.  
Finally, the expression level of CmeABC has been demonstrated to affect the 
frequency of spontaneous ciprofloxacin mutants in such a way that inactivation of 
CmeABC decreases and overexpression of CmeABC increases the frequency of 
emergence of mutations conferring ciprofloxacin resistance (Yan et al., 2006).  
Mutation frequency for macrolide resistance in C. jejuni and C. coli has been revealed 
to be low (~10-10/cell/generation) (Lin et al., 2007). This is congruent with a study 
showing that a single macrolide treatment of Campylobacter-infected chickens did not 
select for erythromycin resistance, in contrast to similar studies conducted with 
fluoroquinolones (Lin et al., 2007). However, continuous use of tylosin in chicken feed 
did result in emergence of erythromycin-resistant C. jejuni and C. coli (Ladely et al., 
2007; Lin et al., 2007).  
Besides spontaneous mutations, Campylobacter are also able to acquire resistance 
determinants by natural transformation, transduction or conjugation, e.g. conjugation of 
tet(O)-carrying plasmids (Zhang and Plummer, 2008). In the presence of antimicrobial 
selection pressure, the bacteria containing these resistance determinants out-compete the 
susceptible bacteria, eventually leading to a resistant strain. 
A predicted 28% of human patients treated with a fluoroquinolone will develop 
resistance against fluoroquinolones (Wistrom and Norrby, 1995; Engberg et al., 2006). In 
addition, the emergence of Campylobacter resistance in human clinical samples has been 
shown to be closely connected to antimicrobial resistance found in animals (Smith et al., 
1999). The transmission of resistant Campylobacter strains has been contemplated in 
several studies, where a temporal association between resistant animal and human strains 
has been investigated (Endtz et al., 1991). Antimicrobial agents with clinical significance 
to treating campylobacteriosis in humans, such as macrolides, fluoroquinolones and 
tetracyclines, have all been used extensively in farm animals as therapeutic agents, 
prophylactics or growth promoters. Since the beginning of large-scale use of 
fluoroquinolones in the early 1990s, the number of resistant Campylobacter strains has 
clearly increased in both farm animals and humans. For example, in a Dutch study, 
fluoroquinolone resistance in 1982 was non-existent in broilers and clinical samples, but 
by 2002–2004 it had reached 35% in broilers and 34% in human clinical samples (Endtz et 
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al., 1991; van Hees et al., 2007). Similarly, in a Finnish study where antimicrobial 
resistance in C. jejuni and C. coli isolates from human clinical samples from 1978–1980 
and 1990 were compared, ciprofloxacin resistance was observed to rise from 0% to 9% 
over a decade (Rautelin et al., 1991). By 1999, 14 % of human clinical isolates were 
ciprofloxacin-resistant (Rautelin et al., 2003). 
A summary of characteristics involved in the emergence of fluoroquinolone, macrolide 
and tetracycline resistance in C. jejuni is presented in Table 7. 
 
Table 7. Resistance characteristics of C. jejuni to macrolides, fluoroquinolones and 
tetracyclines 
 
Characteristic Antimicrobial class Macrolide Fluoroquinolone Tetracycline 
Antimicrobial target 50S rRNA Gyrase 30S rRNA 
Primary resistance 
mechanism Target mutation Target mutation Protein protection 
Emergence of 
resistance 
Spontaneous 
mutation 
Spontaneous  
mutation Conjugation 
Selection of 
resistance Slow, multistep Rapid, single step Rapid, single step 
Fitness Significant fitness cost 
No fitness cost/ 
enhanced fitness 
No fitness cost/ 
enhanced fitness 
Trends in resistance Slow increase Very rapid increase Very rapid increase 
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3 Aims of the study 
The major aim of this thesis was to investigate development of antimicrobial resistance 
and resistance mechanisms in C. jejuni, C. coli and C. hyointestinalis, especially with 
respect to ciprofloxacin. Specific aims were as follows: 
 
 
 
1. To establish the susceptibility profile of Finnish C. hyointestinalis strains to 
a panel of antimicrobial agents  
 
2. To study and compare quinolone resistance mechanisms in C. hyointestinalis 
and C. jejuni  
 
3. To assess the role of efflux in the development of resistance and the effect of 
efflux pump inducers and inhibitors on the antimicrobial susceptibility of C. 
coli, C. jejuni and C. hyointestinalis  
 
4.  To establish the spontaneous mutation frequencies in a group of  C. jejuni 
and C. coli strains 
 
5. To characterize the development and emergence of mutations associated 
with ciprofloxacin resistance in the QRDR of gyrA and in the promoter 
region of the CmeABC-efflux pump 
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4 Materials and methods 
4.1 Bacterial strains and growth conditions 
The 49 C. hyointestinalis subsp. hyointestinalis strains used in Study I were isolated from 
Finnish reindeer and bovine faecal samples. Twenty-four reindeer strains were isolated in 
1998 from faeces contained in the rectums of slaughtered animals (Hänninen et al., 2002), 
and 25 bovine isolates were obtained from rectal faecal samples collected in 
slaughterhouses in Finland in 2003 (Hakkinen et al., 2007), except for strain B704, which 
was isolated in 1998. C. jejuni and C. coli strains used in Studies I-IV are listed in Table 8.  
 
Table 8. C. jejuni and C. coli strains used in Studies I–IV 
 
Species Strain no. Source Study 
C. jejuni 143483 Reference strain (Hakanen et al., 2002a) I 
 ATCC 33560 Reference strain (McDermott et al., 2004) II, III, IV 
 B1 Chicken II, IV 
 B5 Chicken II, IV 
 B42 Chicken II, III 
 B67 Chicken II, III, IV 
 B68 Chicken IV 
 BR1 Chicken II  
 Brt1 Chicken III 
 FB6371 Chicken II  
 6507 Chicken II  
 14/8R Chicken II  
 49/7R Chicken II, III, IV 
 49/7RAT Laboratory-induced mutant* II, III, IV 
 N191 Cattle II  
C. coli B25 Chicken II, III 
 6590 Chicken II, III 
 6590AT Laboratory-induced mutant* II  
 S140R Pig II, III 
 72277 Pig II, III 
 T72498 Pig II  
* Mutants 49/7RAT and 6590AT were obtained by serial passage of strains 49/7R and 
6590, respectively, in increasing concentrations of tetracycline and ampicillin 
 
All strains were grown on Mueller-Hinton (MH) agar (Oxoid Ltd., London, UK), 
supplemented with 5% horse blood or without agitation in MH broth (Oxoid Ltd.) and 
incubated at 37°C for 48 h under microaerobic conditions (5% O2, 10% CO2 and 85% N2). 
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4.2 Antimicrobial agents and efflux pump effectors 
 
Antimicrobial discs and efflux pump effectors used in studies I-III are presented in Table 
9. 
 
Table 9. Antimicrobial discs, efflux pump effectors and the employed concentrations used 
in Studies I, II and III. 
 
Antimicrobial agents, Study I  
Amoxicillin 10 µg 
Co-amoxiclav (amoxicillin + potassium clavulanate) 30 µg 
Ampicillin 25 µg 
Gentamicin 10 µg 
Streptomycin 10 µg 
Lincomycin 15 µg 
Erythromycin 15 µg 
Tetracycline 10 µg 
Doxycycline hydrochloride 30 µg 
Ciprofloxacin 5 µg 
Metronidazole 5 µg 
Compound S3 (sulfadiazine, sulfathiazole, sulfamerazine) 300 µg 
Efflux pump effectors  
Phenyl-arginine-β-naphthylamide (PAβN), Studies I, III 50 mg/l 
1-(1-naphthylmethyl)-piperazine (NMP), Study III 100 mg/l 
Sodium salicylate, Study III 100 mg/l 
Sodium deoxycholate, Study III 1 mg/ml 
Ox biles, Study II 20 mg/ml 
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4.3 Antimicrobial susceptibility testing 
Agar dilution method 
 
Agar dilution was used in all studies and together with broth dilution it is the only 
standard susceptibility testing method for Campylobacter approved by the Clinical and 
Laboratory Standards Institute (CLSI). However, for Campylobacter, no internationally 
accepted minimum inhibitory concentration (MIC) interpretive criteria or resistance cutoff 
values have been established for agar dilution or any of the other methods. In these 
studies, we used veterinary-specific breakpoints generated for the Enterobacteriaceae by 
CLSI (NCCLS, 2002) or epidemiological cut-off values recommended by EUCAST 
(http://www.eucast.org) for C. jejuni or C. coli (see Table 10). 
The method for agar dilution was adapted from CLSI-recommended guidelines 
(NCCLS, 2002). Briefly, a stock solution of antimicrobial agent was prepared and 
incorporated in doubling dilutions into Mueller-Hinton (MH) blood agar plates (for 
concentration ranges for each antimicrobial agent, see Table 10). C. jejuni, C. coli and C. 
hyointestinalis were incubated under microaerophilic conditions in 5 ml of MH broth and 
diluted for a turbidity equivalent of 0.5 McFarland standard. Then, by using a 19-point 
inoculator, bacterial suspensions from up to 19 Campylobacter strains were inoculated on 
MH plates containing different concentrations of antimicrobials, and incubation was 
performed at 37 °C for 48 h under microaerophilic conditions. To control contamination 
and antimicrobial agent carry-over, agar plates containing no antimicrobial agent were 
identically inoculated. After 48 h, for each bacterial suspension the lowest concentration 
of antimicrobial agent that completely inhibited bacterial growth was recorded as the MIC 
value. Quality control strains ATCC 33560 or 143483, for which quality control ranges 
have been established, were included in all studies (Hakanen et al., 2002a; McDermott et 
al., 2004).  
 
Table 10. Concentration ranges and cut-off values for MIC determination of the 
antimicrobial agents used  
 
Antimicrobial agent Concentration range (mg/l) Cut-off value (mg/l) 
Ampicillin  0.125–16 8 
Ciprofloxacin  0.032–128 4 
Erythromycin  0.032–16 16 
Kanamycin 0.5–8 64 
Nalidixic acid  1–512 32 
Rifampicin 2–2048 4 
Tetracycline 0.125–128 16 
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Disc diffusion method 
 
The agar disc diffusion method is a widely used, relatively low-cost method for screening 
antimicrobial susceptibility that provides results classifying isolates as resistant, 
intermediate or susceptible (Watts and Lindeman, 2006). However, breakpoint values for 
resistant Campylobacter have not been established. The agar disc diffusion technique was 
used in Study I to characterize the susceptibility profile of 49 C. hyointestinalis strains to 
12 antimicrobial agents (Table 9). Disc diffusion testing was performed according to 
CLSI-recommended guidelines (Clinical and Laboratory Standards Institute, 2004). 
Briefly, fresh bacterial cultures were incubated for 48 h in microaerophilic conditions in 
5 ml of MH broth and diluted for a turbidity equivalent of 0.5 McFarland standard. The 
bacterial suspension was inoculated on an MH blood agar plate with a sterile swab that 
was streaked over the entire agar surface to ensure even distribution of the suspension. 
After the excess moisture was absorbed, up to three antimicrobial discs (Table 9) were 
applied on one plate with sterile forceps. The plates were incubated at 37°C for 48 h in 
microaerophilic conditions. The results were recorded as the diameters of the zones of 
inhibition in millimetres. C. jejuni 143483 was used as a control strain. 
4.4 Estimation of mutation frequencies 
Mutation frequencies in C. jejuni and C. coli were investigated in Study II using the 
methods of Björkholm et al. (2001) and Wang et al. (2001), with minor modifications. A 
schematic presentation of the process is presented in Figure 5. Briefly, C. jejuni and C. 
coli strains were grown in 5 ml of Brucella broth for 48 h. Then, 30 µl of bacterial 
suspension was used to inoculate each of the 20 tubes containing 3 ml of a Brucella broth. 
Tubes were grown for 48 h at 37°C. After incubation, 500 µl of suspension was spread on 
Brucella agar plate containing 1 mg/l of ciprofloxacin. Plates were incubated for 3–4 days 
in a microaerobic atmosphere at 37°C, and the colonies were counted. If the number of 
colonies was too high, the experiment was repeated using 100 µl of 10-fold dilution for 
the inoculation of the ciprofloxacin-containing Brucella plate.  
The number of viable bacteria was determined in each experiment by plating 10–6, 10–7 
and 10–8 dilutions from three tubes on non-selective Brucella blood agar plates. 
The mutation frequency was calculated as the mean number of colonies found on the 
selective agar plates (cfu/ml) divided by the mean of the total number of viable cells found 
on the non-selective agar plates. 
The effect of ox bile mixture on mutation frequency was determined by comparing two 
simultaneously performed experiments using the same bacterial strain. The two 
experiments were identical to the procedure presented in Figure 5, except that in one 20 g/l 
of ox bile was added to the 20 tubes containing 3 ml of Brucella broth.  
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Figure 5. An overview of the process for calculation of mutation frequencies for a C. 
jejuni or a C. coli strain 
 
 
 
4.5 DNA extraction, purification and sequencing 
DNA was extracted by using the method of Pitcher et al. (1989), modified by Hänninen et 
al. (1996). 
The quinolone resistance-determining region (QRDR) of gyrA was amplified using 
PCR primers and cycling conditions described by Piddock et al. (2003) (Studies I and II) 
and Griggs et al. (2005) (Study IV). The intergenic region between cmeR and cmeA was 
sequenced using PCR primers and cycling conditions described by Lin et al. (2005a) 
(Study II). 
PCR products were purified using the QIAquick PCR Purification Kit (Qiagen, 
Valencia, CA, USA). 
Sequencing was performed using the automated cycle sequencer ABI377XL with Big 
Dye terminators (PE Applied Biosystems, Foster City, CA, USA) at the Institute of 
Biotechnology, University of Helsinki. 
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4.6 Development of mutations after ciprofloxacin challenge 
In Study II, 8 C. jejuni and 2 C. coli strains were subjected to 1 mg/l of ciprofloxacin, and 
DNAs from a total of 19 C. jejuni and 8 C. coli colonies were extracted. The promoter 
binding region between cmeR and cmeA was amplified by PCR and sequenced. 
In Study IV, each of the seven originally ciprofloxacin-susceptible C. jejuni strains 
were challenged to 0.125 mg/l of ciprofloxacin in three independent experiments, after 
which bacterial DNA was extracted. The seven ciprofloxacin induced strains from one of 
the experiments were subcultured on non-selective plates (4 subcultures), on 0.125 mg/l 
ciprofloxacin plates (7 subcultures) and on plates containing increasing concentrations of 
ciprofloxacin, to a maximum of 8 mg/l. DNA was then extracted from the subcultures, and 
the QRDR of gyrA was amplified with primers from Griggs et al. (2005) and sequenced. 
The sequencing chromatogram was analyzed for the presence of mutated and multiple 
peaks in the QRDR of gyrA.  
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5 Results 
5.1 Susceptibility of C. hyointestinalis to antimicrobial agents (I) 
Susceptibility of 24 reindeer and 25 bovine C. hyointestinalis strains to 12 antimicrobial 
agents (see Table 9) was evaluated by using the agar disc diffusion method. The inhibition 
zones were measured in millimeters, and if no inhibition zone was detected, the diameter 
value of the disc, 6 mm, was used, and the strain was considered resistant. Sulphonamides, 
streptomycin, metronidazole, ciprofloxacin and lincomycin failed to produce inhibition 
zones with 6, 8, 1, 1, and 1 C. hyointestinalis strains, respectively, all of which were of 
bovine origin. In addition, minimum inhibitory concentration (MIC) values for 
ciprofloxacin and nalidixic acid were measured for reindeer strains by using the agar 
dilution method. According to the results, all reindeer strains were highly susceptible to 
ciprofloxacin, with MIC values ranging from 0.064 to 0.25 mg/l. The MIC value was 
32 mg/l for the one ciprofloxacin-resistant bovine strain. The results are summarized in 
Table 11.  
 
Table 11. Summary of inhibition zones and MIC values of 49 C. hyointestinalis bovine 
and reindeer strains by using disc diffusion and agar dilution methods 
 
Method Antimicrobial agent 
Bovine strains  
(n=25) 
Reindeer strains 
(n=24) 
Range Mean Range Mean 
Disc diffusion 
(inhibition zone, mm) 
Gentamicin 27–34 29.6 27–42 33.4 
Sulphonamides 6–42 23.7 36–62 43.8 
Streptomycin 6–28 17.8 26–36 31.1 
Erythromycin 25–39 31.9 28–54 34.7 
Metronidazole 6–43 23.0 16–31 22.0 
Ampicillin 38–56 49.8 50–69 58.8 
Amoxicillin 46–56 51.9 55–72 61.4 
Doxycycline 30–45 39.2 36–60 45.5 
Co-amoxiclav 36–54 47.2 50–62 55.3 
Tetracycline 34–49 42.3 42–57 47.6 
Lincomycin 6–31 23.3 11–36 22.3 
Ciprofloxacin 6–53 40.9 38–60 43.8 
Agar dilution  
(MIC, mg/l) 
Ciprofloxacin ND ND 0.064–0.25 0.125 Nalidixic acid 64–128 64 
 
ND = Not done 
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5.2 QRDR sequence analysis of C. hyointestinalis (I)  
The QRDR of gyrA in three ciprofloxacin-susceptible C. hyointestinalis strains (PO0, 
PO61 and PO271) was sequenced. The obtained sequence shared 73% identity with that of 
C. jejuni and was most similar (98%) to the respective sequence in C. fetus. 
PO0, PO61 and PO271 were subjected to increasing concentrations of ciprofloxacin, 
and the QRDR of variants able to grow in 64 mg/l of ciprofloxacin were sequenced as was 
that of C. hyointestinalis strain B704, with a ciprofloxacin MIC of 32 mg/l. Sequence 
analysis showed a Thr-86–>Ile mutation in all of these four strains as a result of a single-
point mutation of cytosine to thymine. No other mutations were detected in the QRDR 
region. When PO0, PO61 and PO271 were isolated from plates containing 16 or 32 mg/l 
of ciprofloxacin, no mutations were detected in the QRDR of gyrA. When these strains 
were subjected to ciprofloxacin (16 mg/l), their resistance to nalidixic acid increased from 
64–128 mg/l to ≥ 512 mg/l. 
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5.3 Mutation frequency of C. jejuni and C. coli (II) 
Mutation frequency of 11 C. jejuni and 5 C. coli strains was investigated on Brucella 
blood agar plates containing 1 mg/l of ciprofloxacin. All of the strains were originally 
ciprofloxacin-susceptible (MIC 0.032–0.25 mg/l). The results are summarized in Table 12.  
The effect of ox bile salts on the mutation frequency of C. jejuni strains ATCC 33560, 
B42, N191, 6507 and B67 and C. coli strain S140R was investigated. The presence of ox 
bile salts in the culture medium had no clear effect on the mutation frequency values in 
any of these strains (data not shown), compared with the experiments conducted without 
bile. 
 
Table 12. Mutation frequency of 11 C. jejuni and 5 C. coli strains obtained from agar 
plates containing 1 mg/l of ciprofloxacin. 
 
Species Strain/origin Mutation frequency Mutabilitya 
C. jejuni ATCC 33560 / reference 2.9 ± 1.4 x 10–6 Strongly hypermutable 
FB6371 / chicken 9.8 ± 1.3 x 10–7 Strongly hypermutable 
B5 / chicken 9.4 ± 1.2 x 10–7 Strongly hypermutable 
B1 / chicken 8.1 ± 1.6 x 10–8 Weakly hypermutable 
BR1 / chicken 4.7 ± 1.2 x 10–8 Weakly hypermutable 
49/7R / chicken 1.6 ± 1.8 x 10–8 Normomutable  
B42 / chicken 1.5 ± 1.8 x 10–8 Normomutable 
N191 / cattle 1.5 ± 1.4 x 10–8 Normomutable 
B67 / chicken 1.0 ± 1.2 x 10–8 Normomutable 
6507 / chicken 9.3 ± 1.2 x 10–9 Normomutable 
14/8R /chicken  4.2 ± 1.1 x 10–9 Hypomutable 
C. coli 6590 / chicken 7.0 ± 2.0 x 10–3 Strongly hypermutable 
B25 / chicken 7.4 ± 1.2 x 10–8 Weakly hypermutable 
S140R / pig 6.2 ± 1.3 x 10–8 Weakly hypermutable 
T72277 / pig 1.5 ± 0.8 x 10–8 Normomutable 
 T72498 / pig 1.3 ± 1.4 x 10–8 Normomutable 
a As defined by Baquero et al. (2004) 
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5.4 cmeR–cmeA sequence analysis of C. jejuni and C. coli (II) 
The intergenic promoter region cmeR-cmeA (Figure 4) was sequenced in 8 C. jejuni and 2 
C. coli ciprofloxacin-susceptible strains. We identified three different sequence types for 
the inverted repeat (IR) sequence located in this region: 
 
Type 1: TGTAAT AAAT ATTACA 
Type 2: TGTAAT AAAA ATTACA 
Type 3: TGTAAT AAA– ATTACA 
 
The strains were transferred on Brucella blood agar plates containing 1 mg/l of 
ciprofloxacin, and DNA from colonies selected from these plates was extracted and the   
promoter-binding region cmeR-cmeA was amplified by PCR and sequenced. The results 
are presented in Table 13. 
 
Table 13. IR sequence types of the intergenic promoter-binding region cmeR-cmeA in 
susceptible parent strains and in strains selected from Brucella agar plates containing 
1 mg/l of ciprofloxacin 
 
Strain/species 
Initial IR 
sequence 
type 
Number of colonies 
selected from the 
selective medium 
IR sequence type of 
colonies selected 
from the selective 
medium 
ATCC 33560 / C. jejuni Type 1 4 All Type 1 
N191 / C. jejuni Type 1 2 All Type 1 
B67 / C. jejuni Type 2 2 Type 1, Type 2 
B5 / C. jejuni Type 1 2 Type 1, Type 2 
14/8R / C. jejuni Type 1 1 Type 1 
FB6371 / C. jejuni Type 2 1 Type 2 
49/7R / C. jejuni Type 2 2 All Type 1 
49/7RAT / C. jejuni Type 3 5 All Type 3 
6590 / C. coli Type 1 3 All Type 1 
6590AT / C. coli Type 1 5 All Type 1 
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5.5 Effect of efflux pump effectors on MIC-values (I, III) 
The effect of putative efflux pump inhibitors PAβN and NMP and putative efflux pump 
inducers sodium salicylate and sodium deoxycholate on MIC values of ciprofloxacin, 
erythromycin, kanamycin, rifampicin and tetracycline was investigated. In study III, six C. 
jejuni strains and four C. coli strains were used as well as six C. jejuni and one C. coli 
variants induced in the presence of 1 mg/l of ciprofloxacin. Further, the effect of PAβN on 
MIC values of ciprofloxacin and nalidixic acid in 17 C. hyointestinalis strains was 
evaluated (Study I). MIC values were obtained by the agar dilution method. An overview 
of these results is presented in Table 14.  
 
Table 14. Effect of putative efflux pump inducers and inhibitors on susceptibility of 6 C. 
jejuni, 4 C. coli and 17 C. hyointestinalis strains to 6 antimicrobial agents. Values 
represent the fold-difference between MIC values obtained in the presence and absence of 
the respective efflux pump effector. 
 
 Nalidixic acid Ciprofloxacin Erythromycin Kanamycin Rifampicin Tetracycline
C. jejuni       
PAβN ND ~* 8–16X ~ 8–64X ~ 
NMP ND ~ 1–8X ~ 2–4X 1–4X
Salicylate ND 1–4X ~ ~ 1–2X ~ 
Deoxycholate ND ~ ~ ~ ~ ~ 
C. coli       
PAβN ND ~ 16–32X ~ 16–32X ~ 
NMP ND ~ 2–8X ~ 2–8X 1–2X
Salicylate ND 2–4X ~ ~ 1–2X ~ 
Deoxycholate ND ~ ~ ~ ~ ~ 
C. hyointestinalis       
PAβN 2–8X ~ ND ND ND ND
MIC values decreased with NMP and PAβN and increased with salicylate and deoxycholate 
* The ~ -sign stands for results that did not reproducibly differ from values obtained in the absence 
of efflux pump effector. 
ND = Not done 
 
The MIC of kanamycin was 4–8 mg/l in C. jejuni strains and 2–8 mg/l in C. coli strains. 
None of the putative efflux pump effectors used had any effect on the kanamycin MIC 
values.  
The MIC of tetracycline was 0.5–8 mg/l in C. jejuni strains and 0.5–64 mg/l in C. coli 
strains. In 15 of the 17 C. jejuni and C. coli strains studied, NMP produced a 2- to 4-fold 
decrease in the MIC value. The other efflux pump effectors had no effect on the MIC 
values of tetracycline. 
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Ciprofloxacin MIC values for the parent strains were 0.063–0.25 mg/l. Ciprofloxacin-
resistant variants of these strains were selected on media containing 1 mg/l of 
ciprofloxacin. The ciprofloxacin MIC values of these variants were 2–64 mg/l. The only 
efflux pump effector producing a change in the ciprofloxacin MIC values was sodium 
salicylate. It increased the MIC values of ciprofloxacin 2- to 4-fold in all C. coli strains 
and in 7 of the 12 C. jejuni strains. 
The effect of PAβN on ciprofloxacin and nalidixic acid MIC values of C. 
hyointestinalis was evaluated. No effect was found on ciprofloxacin, but MIC values for 
nalidixic acid decreased 2- to 8-fold. MIC values for nalidixic acid were from 64 mg/l to 
≥ 512 mg/l, and use of PAβN decreased these values to 16–128 mg/l. 
PAβN and NMP had a pronounced effect on erythromycin and rifampicin MIC values 
of C. jejuni and C. coli. The results of these studies are summarized in Figures 6 and 7.  
 
 
 
Figure 6. Erythromycin MIC values in the presence and absence of PAβN or NMP 
 
 
 
Figure 7. Rifampicin MIC values in the presence and absence of PAβN or NMP 
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5.6 Effect of ciprofloxacin in the development of gyrA mutations 
(II, IV)  
Twelve C. jejuni and 6 C. coli ciprofloxacin-susceptible strains were challenged with 
0.125 and 1 mg/l of ciprofloxacin and by serial passage in 8 mg/l of ciprofloxacin. The 
resulting ciprofloxacin MIC values and corresponding QRDR mutations are presented in 
Table 15. 
Each strain was challenged with 0.125 mg/l of ciprofloxacin in three repeated 
experiments, and the MIC values obtained ranged from 0.25 to 32 mg/l. The presence of 
potential multiple peaks and peaks representing mutated nucleotides in the sequencing 
chromatograms of QRDR of gyrA was investigated. Examination of the sequencing 
chromatogram of QRDR revealed double peaks at codons 86 and 90 in almost every 
chromatogram, and in one case there was a triple peak at codon 86. Only in 2/18 
experiments were no multiple peaks observed. The observed peaks represented codons 
ACA (Thr), ATA (Ile) and GCA (Ala) for amino acid position 86, and codons GAT (Asp), 
AAT (Asn) and GGT (Gly) for amino acid position 90 (Table 16). 
 The results from subsequent studies of the dynamics of the QRDR subpopulations 
after subcultivation in either the presence or absence of ciprofloxacin are presented in 
Table 16.  
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Table 15. Observed QRDR mutations in gyrA and corresponding MIC ranges and median MIC values after challenging C. jejuni and C. coli 
strains with 0.125, 1 or 8 mg/l of ciprofloxacin 
 
Species 
CIP 
challenge 
(mg/l) 
No. of 
studied 
strains/ 
colonies 
Alterations in amino acid positions 86 and 90 in QRDR of gyrA
No mutations Thr86-Ile Asp90-Asn Other mutations
No.a  
MIC 
range 
(mg/l)
Median 
MIC 
value
No.  
MIC 
range 
(mg/l)
Median 
MIC 
value 
No.  
MIC 
range 
(mg/l)
Median 
MIC 
value
No.  
MIC 
range 
(mg/l)
Median 
MIC 
value 
C. jejuni 0.125 6/21 14 0.25-16 2 1 8 8 3 8-16 16 3b 8-32 8 
C. jejuni 1 12/40 9 1-16 1 23 1-16 16 7 2-16 4 1c 2 2 
C. coli 1 6/17 5 2-16 2 9 4-8 8 3 4 4 0 0 0 
C. jejuni 8 7/7 0 0 0 5 16-64 32 2 16-32 24 0 0 0 
a Number of colonies in this group 
b Other mutations in this group were Thr86-Ala x 2 and Asp90-Gly 
c A double mutation Thr86-Ile + Asp90-Asn 
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Table 16. Chromatogram analysis of QRDR sequence data of gyrA in six C. jejuni strains after ciprofloxacin challenge (0.125 mg/l) 
 
Strain 
No challenge 0.125 mg/l challenge 4 passages in MH plates 7 passages in selective plates Serial passage up to 8 mg/l 
Codon 
86 
Codon 
90 MIC 
Codon 
86 
Codon 
90 MIC 
Codon 
86 
Codon 
90 MIC 
Codon 
86 
Codon 
90 MIC 
Codon 
86 
Codon 
90 MIC 
ATCC 
33560 ACA GAT 0.125 
ACA* 
ATA GAT 16 
ACA 
ATA GAT 16 
ACA 
ATA GAT 16 ATA GAT 16 
B1 ACA GAT 0.064 ACA GAT 8 ACA GAT 0.5 ACA ATA 
AAT 
GAT 16 ACA 
AAT 
GAT 16 
B5 ACA GAT 0.125 ACA GAT 16 ACA GAT 0.5 ATA ACA GAT 16 ATA GAT 32 
B67 ACA GAT 0.125 ACA ATA GAT 2 
ATA 
ACA GAT 8 ATA GAT 8 ATA GAT 32 
B68 ACA GAT 0.125 ACA ATA 
GAT 
AAT 0.25 
ATA 
ACA 
GAT 
AAT 8 
ATA 
ACA 
GAT 
AAT 8 
ACA 
ATA 
AAT 
GAT 32 
49/7R ACA GAT 0.064 ACA ATA 
AAT 
GAT 8 
ATA 
ACA 
GAT 
AAT 8 
ATA 
AAT GAT 8 ATA GAT 64 
*Codon represented by the predominant peak is indicated in normal type; codons represented by weaker peaks appear in italics.
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6 Discussion 
6.1 Susceptibility profile of Finnish C. hyointestinalis strains (I) 
C. hyointestinalis is a common Campylobacter species in cattle and reindeer in Finland, 
representing 15.3% and 6% of positive faecal samples, respectively (Hänninen et al., 
2002; Hakkinen and Hänninen, 2009). Since these animals are used for food production 
and C. hyointestinalis has been associated with human disease, it was deemed important to 
establish the susceptibility profile of this species to antimicrobial agents. 
Susceptibility of 49 Finnish C. hyointestinalis strains to 12 antimicrobial agents was 
investigated. According to the results, Finnish C. hyointestinalis strains are susceptible to 
most antimicrobials of veterinary importance, with the exception of sulphonamides (12% 
resistant) and streptomycin (16% resistant). In comparison, in a Canadian study involving 
tetracycline, erythromycin, ampicillin and ciprofloxacin, 10.7%, 10.1%, 1.1% and 0% of 
the 1500 bovine C. hyointestinalis isolates were resistant, respectively (Inglis et al., 2005). 
Interestingly, all of the Finnish resistant C. hyointestinalis strains were of bovine origin, 
and the reindeer strains in general had larger inhibition zones in disc diffusion tests than 
the bovine isolates, suggesting higher susceptibility (Table 11). The mean diameter was at 
least 8 mm larger in reindeer strains than in bovine strains for sulphonamides, 
streptomycin, ampicillin, co-amoxiclav and amoxicillin. This could be explained by 
reindeer living and feeding freely as semi-domesticated animals and only exceptionally 
being treated with antimicrobials. Cattle, on the other hand, are treated, when necessary, 
mostly with penicillins, but also with e.g. tetracyclines, macrolides, lincosamides, 
sulphonamides and aminoglycosides. The overall use of antimicrobials in veterinary 
medicine in Finland is moderate (Table 3). A possible explanation for the high resistance 
rates for tetracycline and erythromycin in the Canadian study could be the use of 
tetracyclines as growth promoters and prophylactics and tylosin as a prophylactic in 
Canadian food animal production (Inglis et al., 2005). 
C. jejuni was isolated from the same bovine faecal samples as C. hyointestinalis, and 
results from the susceptibility determinations are presented in our previous study 
(Hakkinen et al., 2007). Congruently with the bovine C. hyointestinalis isolates, the 
overall prevalence of antimicrobial resistance in bovine C. jejuni isolates was low, as only 
9% of the isolates were resistant to any of the antimicrobial agents tested, most commonly 
to  nalidixic acid (6%) (Hakkinen et al., 2007).  
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6.2 Quinolone resistance mechanisms in C. hyointestinalis (I) 
C. hyointestinalis is inherently nalidixic acid-resistant, but ciprofloxacin-susceptible. Our 
studies showed 73% identity of the QRDR in C. hyointestinalis with that of C. jejuni. 
Nalidixic acid resistance in C. jejuni has been associated with mutations at Ala-70, Thr-86 
or Asp-90 in the QRDR (Wang et al., 1993). However, the mutations associated with 
nalidixic acid resistance in C. jejuni were not present in C. hyointestinalis, and thus, did 
not explain the mechanism of nalidixic acid resistance in C. hyointestinalis. In C. jejuni 
and C. coli, ciprofloxacin resistance is often associated with nalidixic resistance and vice 
versa, although exceptions do occur (Bachoual et al., 2001). Similar cross-resistance was 
observed in our studies, where challenging originally ciprofloxacin-susceptible C. 
hyointestinalis strains with up to 16 mg/l of ciprofloxacin increased the nalidixic acid 
resistance of these same strains from 64–128 mg/l to ≥ 512 mg/l.  
Possible mechanisms for nalidixic acid resistance include decreased antimicrobial 
uptake in the form of increased impermeability of the membrane and action of the efflux 
pumps. The latter was supported by our study, where the presence of efflux pump 
inhibitor PAβN decreased the MIC of nalidixic acid 2- to 8-fold. However, the pump 
inhibitor did not establish complete susceptibility, which could be due to inefficiency of 
the pump inhibitor, function of secondary pump systems or presence of other resistance 
mechanisms, such as those involved in impermeability of the membrane. Thus far, the 
CmeABC-efflux pump has not been characterized in C. hyointestinalis. 
By comparing the QRDR sequence of gyrA in ciprofloxacin-susceptible C. 
hyointestinalis and respective ciprofloxacin-induced variants, we observed that high-level 
ciprofloxacin resistance was associated with the Thr–>Ile mutation in the position 
corresponding to codon 86 in C. jejuni. Therefore, the mechanism of high-level 
ciprofloxacin resistance was the same in C. hyointestinalis as in C. jejuni and C. coli. 
However, this mutation was not observed in variants with MIC of ciprofloxacin < 32 mg/l, 
which could indicate the presence of alternative resistance mechanisms for this lower level 
ciprofloxacin resistance, such as those discussed for nalidixic acid in the previous 
paragraph. The prevalence of this phenomenon was not assessed and possibly Thr86-Ile 
mutations could emerge later, as in Study IV conducted with C. jejuni variants. No other 
mutations in the QRDR of gyrA associated with ciprofloxacin resistance in C. jejuni or C. 
fetus were observed in the C. hyointestinalis strains of this study. Similarly to studies 
conducted with C. jejuni and C. coli, the presence of PAβN did not affect the MIC of 
ciprofloxacin in C. hyointestinalis. 
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6.3 Spontaneous mutation frequency of C. jejuni and C. coli (II) 
Since the majority of resistance mechanisms are associated with target mutations, the rate 
at which mutations occur in bacteria has an impact on the emergence of bacterial 
resistance. Previous to our study, mutation frequency has been characterized in, for 
example, Helicobacter pylori strains and in single C. jejuni and C. coli strains (Taylor et 
al., 1985; Gootz and Martin, 1991; Björkholm et al., 2001; Yan et al., 2006). It is difficult 
to compare results obtained from different studies for several reasons: 1) the same 
antimicrobial is not used in all mutation frequency studies due to different species having 
different inherent resistance profiles, 2) different concentrations of selective agents have 
been used, although this may not always influence the results (Yan et al., 2006), 3) for 
reliable results, the MIC of the bacteria studied to the antimicrobial agent employed 
should always be at least 4-fold smaller than the concentration used for selection (Chopra 
et al., 2003), 4) different methods have been used to conduct and calculate mutation 
frequencies.   
Our mutation frequency determinations revealed that mutation frequencies of 
fluoroquinolone-susceptible C. jejuni and C. coli strains vary considerably, from 
hypomutable to strongly hypermutable. Genetic diversity in general among C. jejuni 
strains is extensive (Dorrell et al., 2001), which may facilitate the adaptation of bacteria to 
the selective environment. Large variance in mutation frequencies has also been observed 
in H. pylori (Björkholm et al., 2001). However, in studies conducted with E. coli, as few 
as 0.7% of strains were of the hypermutable type (Baquero et al., 2004). The high number 
of hypermutable strains in C. jejuni and C. coli could be explained by the lack of such 
repair systems as SOS response and functional methyl-directed mismatch repair (Parkhill 
et al., 2000; Fouts et al. 2005; Gaasbeek et al., 2009). In a recent study of a single C. 
jejuni strain, three functional DNA repair mechanisms, namely nucleotide excision repair 
(NER), base excision repair (BER) and RecA-dependent recombinational repair, were 
identified. None of these affected repair of point mutations, which was analysed by 
determining mutation frequency for mutations conferring nalidixic acid resistance 
(Gaasbeek et al., 2009). Another gene involved in DNA repair in C. jejuni is mfd, which 
encodes a transcription-repair coupling factor. In addition, Mfd increases the rate of 
spontaneous mutation to ciprofloxacin resistance, and ciprofloxacin induces the expression 
of mfd (Han et al., 2008). It is therefore likely that the mutation frequency values obtained 
in our study were influenced by the expression of ciprofloxacin-induced mfd. 
 The obtained mutation frequency values were compared with QRDR and intergenic 
promoter binding cmeR-cmeA sequences derived by sequencing these regions from single 
colonies collected from selective plates used for mutation frequency calculations. 
However, no particular mutation pattern was associated with any of the mutability classes.  
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6.4 cmeR-cmeA sequence analysis of C. jejuni and C. coli (II) 
The transcriptional repressor CmeR represses the expression of the CmeABC efflux pump 
by directly binding to a 97-bp cmeR-cmeA intergenic (IT) region (Lin et al., 2005a). 
Previously, mutations in cmeR have been shown to inhibit the binding of CmeR, resulting 
in overexpression of CmeABC and increased resistance to multiple antimicrobials, 
including ciprofloxacin (Pumbwe et al., 2004; Lin et al., 2005a). CmeR binding can also 
be inhibited by inducing ligands, such as bile salts, which interact with CmeR and cause a 
conformational change that makes it unable to bind DNA (Lin et al., 2005b). In a study by 
Lin et al. (2005), a spontaneous deletion, and in a study by Cagliero et al. (2007), a 
spontaneous transition, in the inverted repeat sequence located in IT, were associated with 
increased resistance (see Table 17). 
In Study II, sequence Types 1 and 2 in the inverted repeat of IT were identified, as well 
as a previously unreported Type 3 (Table 17), both in the original ciprofloxacin-
susceptible C. jejuni and C. coli strains, and in variants selected from plates containing 
1 mg/l of ciprofloxacin. The different sequence types were compared with mutations in the 
QRDR region and MIC values obtained for ciprofloxacin, but no relationship was 
detected. However, sequence Type 3 was exclusively and consistently found in the 
49/7RAT strain, a tetracycline- and ampicillin-induced variant of 49/7R, which is of 
sequence Type 1. The difference in MIC of ciprofloxacin between these strains 
(0.032 mg/l in 49/7R and 0.5 mg/l in 49/7RAT) could be explained by this deletion in the 
IT region.  
A CmeR structural study revealed that CmeR binds the inverted repeat in a relatively 
weak fashion and that CmeR has a very flexible DNA-binding domain, permitting 
recognition of several DNA sites (Routh et al., 2009). This is concordant with the role of 
CmeR as a pleiotropic regulator (Guo et al., 2008). Taking these observations into 
consideration, possibly not  all alterations in the inverted repeat sequence bear significance 
in the binding of CmeR.   
 
Table 17. IR sequence types observed in different studies of the cmeR-cmeA IT region 
 
 
 
IR sequence Reference 
TGTAAT AAAT ATTACA (Lin et al., 2005a) 
TGTAAT AA–T ATTACA (Lin et al., 2005a) 
TGTAAT AAAA ATTACA (Cagliero et al., 2007) 
TGTAAT AAAA ATTATA (Cagliero et al., 2007) 
TGTAAT AAAT ATTACA Study II (Type 1) 
TGTAAT AAAA ATTACA Study II (Type 2) 
TGTAAT AAA– ATTACA Study II (Type 3) 
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6.5 Effect of efflux pump effectors (I, III) 
6.5.1 Inhibitors 
Phenyl-arginine-β-naphthylamide 
 
Of all the putative efflux pump effectors employed in Studies I and III, PAβN had the 
most important effect. It was able to decrease the intrinsic resistance of C. hyointestinalis 
to nalidixic acid 2- to 8-fold, intrinsic resistance of C. jejuni and C. coli to rifampicin 8- to 
64-fold and 16- to 32-fold, respectively, and increase the inherent erythromycin 
susceptibility of C. jejuni and C. coli 8- to 16-fold and 16- to 32-fold, respectively. No 
reproducible effect on the MIC values of ciprofloxacin, kanamycin and tetracycline was 
detected. 
Earlier studies of PAβN on resistant and susceptible erythromycin strains have resulted 
in an 8- to 128-fold decrease in erythromycin MIC levels (Payot et al., 2004; Cagliero et 
al., 2005; Martinez and Lin, 2006; Gibreel et al., 2007). No high-level erythromycin-
resistant C. jejuni were included in our investigation, but according to the study of Gibreel 
et al. (2007), PAβN failed to decrease resistance of high-level erythromycin-resistant C. 
jejuni, which would constitute a major drawback when considering this substance as a 
potential drug candidate against development of resistance. Contrary to this, Martinez and 
Lin (2006) reported the susceptibility to erythromycin to be restored in resistant strains in 
the presence of PAβN.  
In a study involving two C. jejuni strains, rifampin resistance decreased considerably, 
1024- to 2048-fold, and tetracycline resistance decreased up to 512-fold in the presence of 
PAβN (Martinez and Lin, 2006). In our study, no effect of PAβN on tetracycline 
susceptibility was observed. The fact that all strains used in our study had low MIC values 
for tetracycline, unlike the strain evaluated by Martinez and Lin, may explain this 
discrepancy.     
The effect of PAβN on ciprofloxacin and nalidixic acid resistance in C. jejuni and C. 
coli has been investigated previously. In a study by Corcoran et al. (2005), PAβN at a 
concentration of 20 mg/l produced no effect on the MIC of ciprofloxacin or nalidixic acid 
in the ciprofloxacin- and nalidixic acid-resistant strain, but in the two evaluated 
susceptible strains, it produced a 2-fold and a 2.5- to 4-fold increase in ciprofloxacin and 
nalidixic acid susceptibility, respectively. The results obtained by Martinez and Lin (2005) 
by the broth dilution method in the presence of 10 µg/ml of PAβN showed up to a 2-fold 
and a 4-fold increase in ciprofloxacin and nalidixic acid susceptibility, respectively. 
Cagliero et al. (2006b) reported that of the 22 ciprofloxacin-resistant and -susceptible C. 
jejuni and C. coli strains only 3 were able to decrease ciprofloxacin MIC values by more 
than 2-fold. In studies I and III, PAβN had no effect on the ciprofloxacin MIC values of 
resistant and susceptible C. jejuni, C. coli and C. hyointestinalis. It did, however, lower the 
nalidixic acid resistance of C. hyointestinalis 2- to 8-fold, indicating different resistance 
mechanisms for these two related antimicrobials in C. hyointestinalis. 
 
 
 
 
52
To date, PAβN remains the only broad-spectrum efflux pump inhibitor extensively 
characterized in C. jejuni. Unfortunately, its unfavourable pharmacokinetic and 
toxicological profiles prohibit its clinical use (Lomovskaya and Bostian, 2006). 
 
1-(1-naphthylmethyl)-piperazine 
 
Studies with NMP inhibitor showed 1- to 16-fold, 2- to 8-fold and 1- to 4-fold decreases in 
erythromycin, rifampicin and tetracycline MIC levels, respectively, for C. jejuni and C. 
coli. According to these results, NMP is less effective in decreasing MICs of erythromycin 
and rifampicin than PAβN, which is congruent to studies conducted with E. coli and 
Acinetobacter baumannii (Bohnert and Kern, 2005; Pannek et al., 2006). This also 
suggests that the effects conferred by NMP to antimicrobial susceptibility differ from 
those conferred by PAβN. Moreover, neither of these substances renders the strains 
completely susceptible. In addition, inactivation of the CmeABC efflux pump at the 
molecular level has a stronger effect on antimicrobials and impacts a wider range of 
antimicrobials than the use of PAβN or the NMP in C. jejuni and C. coli (Cagliero et al., 
2006b). The mechanism underlying the ability of NMP to increase antimicrobial 
susceptibility warrants further investigations, and, to our knowledge, the suitability of 
NMP for therapeutic use has not been determined. 
6.5.2 Inducers 
Salicylate  
 
In Study III, sodium salicylate increased ciprofloxacin and rifampicin resistance 1- to 4-
fold and 1- to 2-fold, respectively, in C. coli and C. jejuni. A similar small effect on 
ciprofloxacin resistance in C. jejuni and C. coli was reported earlier by Randall et al. 
(2003). In the same study, Randall et al. observed an increase in tetracycline and 
erythromycin MIC levels in the presence of sodium salicylate, but these findings were not 
confirmed in our study. Salicylate has been shown to decrease the susceptibility of E. coli 
by altering membrane proteins and inducing efflux pumps (Price et al., 2000). This is of 
concern since salicylates are common constituents of non-steroidal anti-inflammatory 
drugs, which are used in combination with antimicrobials to treat microbial diseases. 
 
Bile salts  
 
The CmeABC efflux pump has been established to confer resistance to bile salts present in 
the intestinal tract of the host animal, and bile salt resistance is a prerequisite for 
successful colonization of C. jejuni (Lin et al., 2003). Further, various bile salts, including 
deoxycholate, strongly increase the expression of CmeABC, mainly by inhibiting the 
binding of CmeR to the promoter region of cmeABC (Lin et al., 2005b). The presence of a 
bile salt, taurocholate, has been shown to moderately decrease the susceptibility of C. 
jejuni to, for instance, ciprofloxacin and erythromycin (2-fold change) (Lin et al., 2005b).  
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Bile salts were included in Studies II and III. In Study II, the effect of ox bile on mutation 
frequencies of five C. jejuni and one C. coli strain was investigated by including 20 mg/ml 
of ox bile in the culture media, but no marked impact emerged relative to studies 
conducted without bile salts. In Study III, the effect of 1 mg/ml of sodium deoxycholate 
on the susceptibility of five C. jejuni and four C. coli strains to various antimicrobials was 
evaluated. Apart from variable 2-fold increases in rifampicin MIC values found in each 
round of testing, deoxycholate had no influence on antimicrobial susceptibility of the 
strains examined. Interestingly, although bile salts included in the culture medium of C. 
jejuni resulted in a 6- to 16-fold increase in the expression of cmeABC (Lin et al., 2005b), 
their effect on ciprofloxacin MIC values was negligible. 
6.6 Development and emergence of QRDR mutations (IV) 
 
In Studies II and IV, MIC values and QRDR alterations were investigated after subjecting 
originally ciprofloxacin-susceptible C. jejuni and C. coli strains to 1 mg/l or 0.125 mg/l of 
ciprofloxacin, respectively. In Study IV, the experiment was extended by investigating the 
persistence of these alterations in the presence and absence of ciprofloxacin and also at a 
higher concentration of ciprofloxacin (8 mg/l). 
 
Primary challenge 
 
Initial ciprofloxacin challenge of C. jejuni with 0.125 mg/l produced MIC values of 0.25–
32 mg/l, and challenge with 1 mg/l produced MICs of 1–16 mg/l in C. jejuni and 2–
16 mg/l in C. coli. Pumbwe et al. (2005) obtained similar results with a C. jejuni strain 
challenged with 0.5 and 1 mg/l of ciprofloxacin, giving rise to MIC levels of 32 mg/l. 
Surprisingly, of the 78 colonies studied from 12 C. jejuni and 6 C. coli strains subjected to 
0.125 or 1 mg/l of ciprofloxacin, 28 (36%) had no mutation in their QRDR region despite 
elevated MIC values from 0.25 to 16 mg/l, the median being 2 mg/l. Resistant strains 
without QRDR mutations have previously been reported in clinical and animal isolates 
(Piddock et al., 2003; Hakanen et al., 2003). The proportion of colonies not possessing a 
QRDR mutation was highest (67%) in colonies subjected to 0.125 mg/l of ciprofloxacin. 
The most common mutation type was Thr86-Ile (42%), followed by Asp90-Asn (17%). 
Other observed mutation types were Thr86-Ala, Asp90-Gly and the double mutation 
Thr86-Ile + Asp90-Asn. Repeated challenges or different colonies of the same strain often 
produced different QRDR profiles and MIC values.  
In Study IV, primary challenge with 0.125 mg/l of ciprofloxacin generated multiple 
peaks in the sequencing chromatogram at mutation-prone codons 86 and 90 in QRDR. 
This is indicative of different bacterial subpopulations with variable QRDR sequences that 
are most likely present in the susceptible strain already prior to the ciprofloxacin 
challenge. When subjected to ciprofloxacin challenge, the QRDR subpopulations 
conferring ciprofloxacin resistance became significantly amplified. These findings suggest 
that the sequencing results of a QRDR of a ciprofloxacin-resistant strain may, in some 
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cases, be interpreted as not containing a mutation, although actually the sample contains 
both QRDR-mutated and unmutated bacteria. 
 
Persistence studies 
 
After the preliminary exposure of strains to 0.125 mg/l of ciprofloxacin, the strains were 
either subcultured seven times on plates containing 0.125 mg/l of ciprofloxacin or 
transferred on plates without a selective agent and subcultured four times. The presence of 
multiple peaks at codons 86 and 90 persisted during several subcultures, both after the 
removal of selection pressure and on the selective plates. These results indicate that both 
mutated and unmutated bacteria are able to persist in the absence and presence of 
0.125 mg/l of ciprofloxacin. The persistence of ciprofloxacin-resistant strains in the 
absence of selection pressure has also been reported in vivo (Luo et al., 2005). Apart from 
C. jejuni strains B1 and B5, the high MIC values obtained during the preliminary exposure 
persisted or increased. 
A QRDR-independent resistance mechanism was also activated by the presence of low 
ciprofloxacin concentration. The C. jejuni strains B1 and B5 behaved differently from the 
other strains. After the primary challenge with ciprofloxacin, they presented wild-type 
QRDR sequences and had no multiple peaks at codons 86 and 90, but nevertheless 
expressed ciprofloxacin MIC values of 8–16 mg/l. When the selection pressure was 
removed, their MIC values decreased to 0.5 mg/l (original MIC 0.125 mg/l), whereas in 
other strains showing multiple peaks in the QRDR sequencing chromatogram, the high 
MIC values obtained during preliminary exposure persisted or increased. On the other 
hand, when the subcultivation of strains B1 and B5 was continued in the presence of 
ciprofloxacin, secondary peaks appeared in the sequencing chromatogram, and the MIC of 
ciprofloxacin remained at 16 mg/l. The QRDR-independent resistance mechanism may be 
speculated to involve the action of an efflux pump, which is then replaced or 
supplemented by resistance conferring mutations when selection pressure is prolonged. 
The experiment was continued by serial passage of the strains on plates containing 
increasing concentrations of ciprofloxacin, until 8 mg/l was attained. This resulted in 
strains with either the Thr86-Ile or Asp90-Asn mutation and notably reduced the number 
of double peaks in the sequencing chromatogram. The measured ciprofloxacin MIC values 
were 16–64 mg/l. The appearance of different mutant types after low-level 
fluoroquinolone challenge has also been reported for Mycobacterium by Zhou et al. 
(2000). Concordant with our study, low-level fluoroquinolone challenge selected for 
QRDR-independent resistant mutants, and increasing the fluoroquinolone concentration 
subsequently led to QRDR mutants and reduced the number of different mutant types. 
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7 Conclusions 
 
1. Finnish C. hyointestinalis strains are susceptible to most antimicrobials of veterinary 
importance. However, 32% and 24% of bovine strains were resistant to streptomycin and 
sulphonamides, respectively. Reindeer strains remained susceptible to all tested 
antimicrobials. The difference in the susceptibility profile of bovine and reindeer strains 
most probably reflects the veterinary use of these substances in bovine husbandry, but not 
in reindeer. 
 
2. The QRDR of gyrA in C. hyointestinalis showed 73% identity with that of C. jejuni. 
Mutations associated with nalidixic acid resistance in C. jejuni were not found in the 
QRDR of C. hyointestinalis, and thus, do not explain the inherent nalidixic acid resistance 
of C. hyointestinalis. Inherent nalidixic acid resistance is partly associated with efflux 
pumps since PAβN, an efflux pump inhibitor, decreased the nalidixic acid resistance in C. 
hyointestinalis 2- to 8-fold. However, low nalidixic acid MIC values were not obtained, 
which indicates the presence of other resistance mechanisms. Cross-resistance between 
nalidixic acid and ciprofloxacin was observed in C. hyointestinalis, as induced 
ciprofloxacin resistance also increased MIC values for nalidixic acid. High-level 
ciprofloxacin resistance (> 32 mg/l) in C. hyointestinalis was associated with the same 
Thr86-Ile mutation as in C. jejuni, but no mutations in the QRDR were detected at lower 
ciprofloxacin MIC levels. 
 
3. The impact of efflux pump effectors on erythromycin, ciprofloxacin, tetracycline, 
rifampicin and kanamycin MIC values in C. jejuni and C. coli was investigated. Efflux 
pump inhibitor PAβN increased the susceptibility of C. jejuni and C. coli to erythromycin 
and rifampicin 8- to 32-fold and 8- to 64-fold, respectively. In addition, it decreased the 
nalidixic acid MIC values of C. hyointestinalis 2- to 8-fold. Another inhibitor, NMP, 
produced 1- to 8-fold, 2- to 8-fold and 1- to 4-fold decreases, respectively, in 
erythromycin, rifampicin and tetracycline MIC levels for C. jejuni and C. coli. Neither of 
these inhibitors had an effect on ciprofloxacin MIC values. The different results produced 
by these inhibitors indicate different modes of function for these pump inhibitors.  
An efflux pump inducer, sodium salicylate, was only able to increase the MIC values 
of one of the antimicrobials evaluated, ciprofloxacin (2- to 4-fold). Bile salts, which are 
putative efflux pump inducers, had no observable effect on the MIC values of any of the 
antimicrobials, nor did it have a notable impact on the mutation frequencies of C. jejuni 
and C. coli strains.  
 
4. Mutation frequencies of C. jejuni and C. coli strains varied considerably, from strongly 
hypermutable (2.9 ± 1.4 x 10–6) to hypomutable (4.2 ± 1.1 x 10–9). The proportion of 
hypermutable strains was much higher than previous reports for E. coli, which may 
facilitate the adaptation of C. jejuni and C. coli to a selective environment. No correlation 
was found between mutation frequency and mutations in the QRDR or cmeR-cmeA region. 
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5. Low-level ciprofloxacin concentration (0.125 mg/l) in a medium of originally 
ciprofloxacin-susceptible C. jejuni strains gave rise to multiple peaks in the sequencing 
chromatograms of QRDR, which may reflect different QRDR subpopulations. Exposure 
to 0.125 mg/l of ciprofloxacin resulted in C. jejuni variants with MIC values ranging from 
0.25 to 16 mg/l. Mutations in codon 86 (ACA, Thr) of QRDR included ATA (Ile) and 
GCA (Ala), and mutations in codon 90 (GAT, Asp) included AAT (Asn) and GGT (Gly).  
In two strains, MIC levels of up to 32 mg/l for ciprofloxacin were obtained, but no 
mutations or multiple peaks in the sequencing chromatograms of QRDR were observed. 
This suggests the presence of a QRDR-independent resistance mechanism. The strains 
expressing the resistance mechanism, which involves different QRDR subpopulations, are 
able to persist in both the presence and absence of low-level ciprofloxacin concentration. 
However, the QRDR-independent resistance mechanism is quickly replaced or 
supplemented by the appearance of QRDR mutations if ciprofloxacin challenge persists.  
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